Inhibitory Kappa B Kinase α (IKKα) Inhibitors That Recapitulate Their Selectivity in Cells against Isoform-Related Biomarkers by Anthony, NG et al.
Inhibitory Kappa B Kinase α (IKKα) Inhibitors That Recapitulate Their
Selectivity in Cells against Isoform-Related Biomarkers
Nahoum G. Anthony,† Jessica Baiget,† Giacomo Berretta,† Marie Boyd,† David Breen,‡ Joanne Edwards,§
Carly Gamble,† Alexander I. Gray,† Alan L. Harvey,† Sophia Hatziieremia,† Ka Ho Ho,†
Judith K. Huggan,† Stuart Lang,‡ Sabin Llona-Minguez,† Jia Lin Luo,† Kathryn McIntosh,†
Andrew Paul,† Robin J. Plevin,† Murray N. Robertson,† Rebecca Scott,† Colin J. Suckling,‡
Oliver B. Sutcliﬀe,† Louise C. Young,† and Simon P. Mackay*,†
†Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0NR,
Scotland, United Kingdom
‡WestCHEM Department of Pure and Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow G1 1XL,
Scotland, United Kingdom
§Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road,
Glasgow G61 1QH, Scotland, United Kingdom
*S Supporting Information
ABSTRACT: IKKβ plays a central role in the canonical
NF-kB pathway, which has been extensively characterized. The
role of IKKα in the noncanonical NF-kB pathway, and indeed
in the canonical pathway as a complex with IKKβ, is less well
understood. One major reason for this is the absence of
chemical tools designed as selective inhibitors for IKKα over
IKKβ. Herein, we report for the ﬁrst time a series of novel,
potent, and selective inhibitors of IKKα. We demonstrate
eﬀective target engagement and selectivity with IKKα in U2OS
cells through inhibition of IKKα-driven p100 phosphoryla-
tion in the noncanonical NF-kB pathway without aﬀecting
IKKβ-dependent IKappa-Bα loss in the canonical pathway.
These compounds represent the ﬁrst chemical tools that can be used to further characterize the role of IKKα in cellular signaling,
to dissect this from IKKβ and to validate it in its own right as a target in inﬂammatory diseases.
■ INTRODUCTION
Nuclear factor-κB (NF-κB) transcription factors are central
coordinators of the innate and adaptive immune response and
play key roles in cancer development and progression.1,2
NF-κBs also have a major role in controlling the ability of both
preneoplastic and malignant cells to resist apoptosis and sup-
port tumor angiogenesis and invasiveness.1,2 The signaling
pathways that mediate the activation of the diﬀerent NF-κB
complexes are therefore attractive targets for new chemother-
apeutic interventions.
The NF-κB pathways, which are regulated by the inhibitory
κB kinases (IKKs), are elevated when homeostasis is disrupted.
This is represented by an increase in constitutive IKKα/β
activity leading to enhanced NF-κB expression and subsequent
nuclear localization. The IKKs are upstream regulators of the
NF-κBs, which exist as either homo- or heterodimers bound to
inhibitory kappa Bs (IκB’s).1,2 The activation of these IKK
complexes dictates the phosphorylation, targeted ubiquitina-
tion, and proteolytic removal of IκBs in the canonical pathway
and the phosphorylation and processing of high molecular
weight NF-κB proteins (p100) in the noncanonical pathway.1,2
This in turn allows NF-κB complexes to translocate to the
nucleus and bind speciﬁc promoter regions of their targeted
genes. Studies3,4 have indicated that IKKα and IKKβ play key
but divergent roles in the regulation of global NF-κB signaling
and many aspects of cellular transcription. IKKβ controls the
canonical pathway via activation of p65 RelA−p50 hetero-
dimers,5−7 and its inhibition leads to a reduction in pro-
inﬂammatory gene expression in several cell types. This is
relevant to cancer because several pro-inﬂammatory species
associated with tumor development and progression are encoded
by genes regulated through the IKKβ-NF-κB axis.3,4,6 IKKα has
been shown to have a minor role in the canonical pathway4,6
but is pivotal in the noncanonical pathway, catalyzing the
phosphorylation and proteolytic processing of p100 NF-κB2
which in turn liberates distinct NF-κB p52/RelB dimers and
initiates transcription of a speciﬁc subset of genes. IKKα and
IKKβ have speciﬁc cellular functions,3,8,9 and the selec-
tive inhibition of one isoform over the other may provide a
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useful and novel therapeutic strategy in cancer and inﬂamma-
tory diseases.
Over the past 15 years, many inhibitors of IKKβ have been
reported,10−13 primarily toward developing clinical agents to
treat inﬂammatory conditions such as asthma. However, recent
studies suggest there may be signiﬁcant toxicity and side eﬀects
associated with IKKβ inhibition, including the development of
inﬂammatory skin disease and sensitization of colonic epithe-
lium to a range of insults.14 In addition, IKKβ knockout mice
display severe liver dysfunction.15 Intestinal and liver tox-
icity have also been an issue in several clinical trials of IKKβ
inhibitors which may further limit their clinical applications.
Some IKKα inhibitors have been described in the patent litera-
ture but with little detail regarding activity and speciﬁcity.16
Asamitsu et al.17 reported that the natural product, norarister-
omycin (NAM), inhibits IκBα phosphorylation and degrada-
tion upon TNFα stimulation and prevents p65 phosphorylation
through selective IKKα inhibition. However, the pharmacody-
namic readouts used were reporters for both IKKβ and IKKα
activity in cells and do not focus on speciﬁc biomarkers of
the IKKα-controlled noncanonical pathway such as p100 phos-
phorylation and subsequent processing to p52.
Given the growing evidence that IKKα has an important
role in a number of cancers,18−20 selective IKKα inhibitors are
required in order to fully understand and validate its role in
cancer development and progression, particularly in pros-
tate,19,21 breast,22−24 and pancreatic25−27 cancers. Herein we
describe the design, synthesis, and evaluation of a series of
4-substituted 2-amino-5-cyanopyrrolo[2,3-d]pyrimidines as
part of our program to develop isoform selective IKKα inhib-
itors. We present a comparison of the kinase domains of IKKα
and IKKβ based on molecular dynamics simulations to explore
diﬀerences in conformational ﬂexibility that would enable small
molecule inhibitors to discriminate between the two isoforms.
Finally, we report the ﬁrst example of IKKα-selective compounds
that recapitulate activity in cells against isoform-related pharma-
codynamic readouts.
■ RESULTS AND DISCUSSION
Strategy for Discriminating between IKKα and IKKβ.
To date, no group has been able to successfully crystallize IKKα
and report a high resolution structure of suﬃcient detail to
guide structure-based inhibitor design. To explore diﬀerences
between the two IKK isoforms, we built a homology model of
Figure 1. Sequence alignment for the kinase domains of IKKα and IKKβ (4KIK_chainB) showing 61% of identical residues (colored in turquoise), a
further 14% similar residues (polar for polar, hydrophobic for hydrophobic; in light blue), and 25% nonsimilar residues (white).
Figure 2. (left) Minimized average structure of IKKβ highlighting residues that are identical to (turquoise), similar to (light blue), or diﬀerent from
(white) IKKα. The ATP analogue marks the ATP binding site and is surrounded by turquoise residues. (right) Residual ﬂuctuations of IKKα (black
line) and IKKβ (blue line) arising during the MD simulations. Several areas were found to be more ﬂexible in IKKα (red underline).
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the IKKα kinase domain based on the crystal structure of
IKKβ (chain B, residues 1−309, PDB entry 4KIK),28 keeping
the inhibitor (KSA700 in the pdb ﬁle) and water molecules
found within 6 Å of the protein−inhibitor complex (Figure 1).
Both IKK kinase domains were solvated and then subjected to
extended molecular dynamics, with an average structure gen-
erated for the last 21 ns (IKKα) or 26 ns (IKKβ) and sub-
sequently minimized.
When superimposing the presimulated structures of both
IKK isoforms, it was striking to see that regions making up the
ATP-binding pocket were essentially identical (Figure 2, left).
However, analysis of descriptors of motion extracted from their
MD trajectories such as residual ﬂuctuation revealed dynamic
diﬀerences between the two isoforms that could potentially be
exploited in an inhibitor design program.
Residual ﬂuctuations obtained from the MD trajectories
highlighted areas of the IKKs that acted diﬀerently during the
simulations (Figure 2, right). Overall, the two isoforms behaved
very similarly but IKKα appeared more ﬂexible in several key
areas around the ATP binding site, particularly at the G-loop
(residues 22−27) above the site entrance and the loop located
just adjacent to the hinge (residues 155−159 in IKKα (VGGKI)
and residues 156−160 in IKKβ (GEQRL)). Two residues could
account for the diﬀerences observed with the G-loop: Pro52
Figure 3. Superimposition of IKKα (white) and IKKβ (blue) highlighting the diﬀerences near/in the ATP binding site (marked by the staurosporine
analogue as a stick model) between the two isoforms. The expanded area shows equivalent residues in IKKα (Asn28, Leu48, and Thr52) and IKKβ
(Asn28, Gln48, and Pro52) engaged in diﬀerent interactions/structural eﬀects, resulting in Asn28 being available to interact with putative ligands in
the binding pocket of IKKα but not IKKβ.
Figure 4. (left) Loop conformation located below the active site in IKKα (white) and IKKβ (blue) and its relationship with α-helix 3 residue Asp127
(IKKα)/Asp128 (IKKβ). In IKKβ, Arg159 makes a reciprocal hydrogen bond dimer interaction with Asp128, whereas in IKKα Lys158 has no close
interactions with Asp127. (right) Side chain amine nitrogen (Lys158 (IKKα)/Arg159 (IKKβ)) to side chain acid oxygen (Asp127 (IKKα)/Asp128
(IKKβ)) distance throughout the equilibrated phase of the simulation.
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Table 1. Biochemical Inhibitory Data for the N4-Substituted 2-Amino-5-cyanopyrrolo[2,3-d]pyrimidinesa
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and Gln48 in IKKβ (Thr52 and Leu48 in IKKα) induce a
tension at the tip of the ﬁrst α-helix through proline’s intrinsic
structure and the engagement of the glutamine side chain in a
reciprocal H-bond dimer arrangement with the side chain
amide of Asn28 (Figure 3). This asparagine is located at the
end of the G-loop, and its interaction with Gln48 restrained the
G-loop movement by more than 1 Å in IKKβ when compared
with IKKα. A diﬀerent dynamic behavior was observed with
IKKα, as the equivalent residues do not impose restraints on
the G-loop movements: Thr52 has no rigid turn restriction like
Pro52 in IKKβ, and the side chain of Leu48 seeks a hydro-
phobic environment and will not engage in H-bond formation
with Asn28, leaving the side chain of this latter residue free to
make interactions in the ATP binding site of IKKα (in contrast
to being sequestered by Gln48 as in IKKβ) (Figure 3). The
other signiﬁcant diﬀerence was related to the VGGKI loop
(residues 155−159) in IKKα (residues GEQRL: 156−160 in
IKKβ). In this case, one residue is responsible for the change
observed in residual ﬂuctuation: Lys158 in IKKα is replaced by
Arg159 in IKKβ. The slightly longer arginine side chain and its
Table 1. continued
aKi values are expressed in μM units and are the result of three independent experiments.
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bifurcate H-bonding capacity forms a reciprocal H-bond dimer
with the side chain carboxylate of Asp128 in IKKβ that was
maintained throughout the simulation, while the equivalent
lysine in IKKα never engaged in a strong interaction with the
equivalent Asp127 in IKKα (Figure 4). This interaction in
IKKβ is responsible for tethering the 156−160 loop to α-helix 3
(Asp128 is located in the middle of this helix), thus reducing its
ﬂexibility compared with IKKα.
With respect to putative inhibitor binding, the implications
for isoform selectivity of these two sets of diﬀerences in the
ATP site are 2-fold: ﬁrst, it should be possible to design small
molecules that target the free Asn28 side chain amide presented
at the back of the IKKα pocket that is otherwise engaged in
IKKβ (Figure 3), and second, because the ATP binding pocket
has greater ﬂexibility in IKKα, it has the potential to accommo-
date larger substituents, particularly below the G-loop.
Initial Hit Identiﬁcation. To identify hits that could be
developed to exploit the diﬀerences between the two isoforms,
we screened our in-house compound library compiled of frag-
ments designed to target the common hinge-binding motif
found in protein kinases. Using a DELFIA kinase assay kit with
minor modiﬁcations29 to measure IKKα and IKKβ inhibitory
activity, we identiﬁed 2-amino-4-chloro-5-cyanopyrrolo[2,3-d]-
pyrimidine 4 as our primary hit (Table 1). On the basis of the
assumption that the 2-aminopyrrolo[2,3-d]pyrimidine core of
compound 4 was binding at the hinge of IKKα, we varied
substitution at the 4-position widely. Diﬀerences in bulk and
polar functionality were incorporated to exploit the greater
Scheme 1a
aReagents and conditions: (a) Ac2O, DMF, 150 °C, 4 h; (b) PivCl, pyridine, 85 °C; (c) POCl3, DMA; (d) amine, Et3N, 1,4-dioxane
200 °C (μW) 20 min; (e) amine, Et3N, n-BuOH, reﬂux, 16 h then KOH, EtOH, 80 °C, 20 h; (f) boronic acid/ester, Pd(dppf)Cl2, KOAc,
H2O/dioxane, 110 °C 16 h.
Scheme 2a
aReagents and conditions: (a) NBS, (PhCO2)2, CCl4, 90 °C, 1 h; (b) NH(Bn)2, CCl4, rt, 12 h, 70%; (c) OsO4, NMO, acetone/H2O, rt, 4 h, 71%,
96:4 dr; (d) BzCl, pyridine, 0 °C to rt, 24 h, 84%; (e) H2 (1 atm), Pd(OH)2, rt, 16 h, 98% (f) 5, Et3N, n-BuOH, reﬂux, 16 h then KOH, EtOH
80 °C, 20 h, 42%.
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ﬂexibility in the IKKα ATP binding site and the position of the
Asn28 side chain at the back of the pocket.
Chemistry. The general route used to prepare N4-substituted
2-amino-5-cyanopyrrolo[2,3-d]pyrimidines for assessment began
with the preparation of 1 using a published procedure.30 1 was
then protected as either its diacetyl derivative 2 or pivaloyl
derivative 3, which were subsequently converted to the aryl
chlorides 4 and 5 (Scheme 1) and used to prepare an initial
series of compounds (4−31) (Table 1) by nucleophilic aromatic
substitution with a range of primary and secondary amines. The
second series of aryl cross coupled compounds exploring the
4-phenyl 2-amino-5-cyanopyrrolo[2,3-d]pyrimidines was prepared
by Suzuki−Miyaura couplings (43−62) with 5. In general, the use
of the N-pivalamide 5 gave higher yields of the ﬁnal compounds
compared to the unprotected form 4.
To explore polar functionality further in the N4-substituted
2-amino-5-cyanopyrrolo[2,3-d]pyrimidines, a series of amino
alcohol derivatives (23−31) was prepared as analogues of 16.
Compounds 23−29 were prepared from commercially available
amines using the procedure detailed in Scheme 1. To incor-
porate 4-substituents with more than one hydroxyl group in the
cyclopentane ring as in the putative IKKα selective inhibitor
NAM,17 we prepared the diol 30 and triol 31.31 The synthesis
of 30 began with bromination32 of cyclopentene 32 to produce
Scheme 3a
aReagents and conditions: (a) Pd(PPh3)4, PPh3, NaH, NH(BOC)2, THF/DMF, 50 °C 24 h, 42%; (b) OsO4, NMO, acetone/H2O, rt, 24 h, 89%;
(c) BzCl, pyridine, 0 °C to rt, 17 h, 74%; (d) 4 N HCl in 1,4-dioxane, 0 °C to rt, 16 h, 76%; (e) 7, Et3N, nBuOH, reﬂux, 16 h then KOH, EtOH
80 °C, 20 h, 33%.
Table 2. Biochemical Inhibitory Data for the 4-Phenyl 2-Amino-5-cyanopyrrolo[2,3-d]pyrimidine Seriesa
aKi values are expressed in μM units and are the result of three independent experiments.
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the unstable halide 33, which was immediately treated with
N,N-dibenzylamine. The resulting allylic amine 34 underwent
syn-dihydroxylation to aﬀord the diol 3533 with excellent dia-
stereoselectivity, which was then protected as the dibenzoate
36. The amine was subsequently deprotected by hydrogenation
to yield 37, which was coupled with 5. Global deprotection
gave the desired ﬁnal product 30 (Scheme 2).
To prepare the triol 31, the allyl acetate 38 was reacted with
sodium di-tert-butyl iminodicarbonate34,35 to produce 39,
which was oxidized to the syn-diol 40 followed by benzoate
protection of the hydroxyl functionalities to give 41 and
removal of the BOC groups under acidic conditions to yield the
amine 42. This was then coupled with 5 followed by basic
hydrolysis to remove the protecting groups to give the desired
ﬁnal product 31 (Scheme 3).
An obvious progression from this series was to replace the
bulky saturated ring with a phenyl ring bearing a selection of
polar o-, m-, or p-substituents. This series was prepared by reac-
ting 5 with a variety of boronic acids or esters under Suzuki−
Miyaura coupling conditions to aﬀord the products 43−62
(Scheme 1; Table 2).
To assess the importance of the 2-amino and 5-cyano groups for
activity and selectivity, we purchased (63) or prepared compounds
(64−71) without either or both substituents (Scheme 4, Table 3).
Structure−Activity Relationship Studies. In the N4-sub-
stituted series (Table 1) several compounds had similar Ki
values against IKKα compared to the initial hit 4. For example,
compounds with aliphatic substituents retained potency and
selectivity against IKKα and had the potential to be improved
through further derivatization. Inhibitory activity for the sec-
ondary amines (7, 8, and 9) suggests the presence of a
restricted lipophilic pocket in IKKα, which could be responsible
for a 5-fold increase in potency from the methylamine analogue
7 to the cyclohexylamine derivative 9. However, the inactivity
of the compound with the bulkier cyclohexylmethylamino
group (10) suggested that this lipophilic pocket was limited in
size. In contrast, the more planar phenyl and benzyl analogues
(11 and 14) were found to be less active than 9, and the
insertion of polar substituents in the para position of the aniline
group produced no signiﬁcant improvement in activity (12 and
13). Conversely, the insertion of polar groups in more ﬂexible
side chains was tolerated (16), which suggested the presence of
a polar region adjacent to the lipophilic pocket.
Although compounds with a piperidyl side chain (17 and 18)
were found to be active, other tertiary amines at position 4
were not tolerated (19−22), which could be due to additional
heteroatoms not being accepted in a lipophilic area of the binding
directly proximal to position 4 of the pyrrolo[2,3-d]pyrimidine
scaﬀold. By contrast, the activity of 16 suggested that a ﬂexible
ethyl chain is able to direct the heteroatom away from this
lipophilic region and possibly engage an adjacent polar region
more eﬀectively.
Removal of the hydrogen bond donor (HBD) from the
4-amino substituent by replacing the secondary cyclohexylami-
no group in 9 with the tertiary N-methylcyclohexylamine (10)
abrogated activity. However, the activity of piperidyl analogue
17 suggests that a HBD at the 4-position is not an absolute
requirement for inhibition of IKKα. The inactivity of com-
pound 10 can be explained by rotation of the N-methyl (and
hence the cyclohexyl group) substituent orthogonal to the
pyrrolo[2,3-d]pyrimidine moiety to reduce steric clash with the
5-cyano substituent and generate a conformation that is no
longer compatible with the binding site.
On the basis of the activity of the 4-hydroxyethylamino deriv-
ative 16, we prepared a second series of amino alcohol deriv-
atives (Table 1). Extending the alkyl chain of 16 from ethyl to
propyl was detrimental to activity (23), whereas the cyclic ana-
logues produced more interesting results. The (R)-pyrrolidin-3-
ol enantiomer 25 was active and selective against IKKα,
whereas the (S)-enantiomer 24 was inactive, suggesting the
directionality of the hydroxyl group had a major inﬂuence
on activity and selectivity. On the other hand, the (R)- and
(S)-pyrrolidin-2-yl methanol enantiomers 26 and 27 shared the
same activity and selectivity against IKKα, implying that free
rotation around the methyl alcohol is suﬃcient to allow equiv-
alent interactions.
The trans-aminocyclohexanol derivative 28 was also active
and selective against IKKα, but the cyclohexylamino ethyl
alcohol 29, designed as a hybrid of compounds 8 and 16,
proved to be inactive. Like compound 10, this is probably due
to the aliphatic ring and the ethyl chain being twisted 90° away
from the nitrile axis to adopt a more energetically favored
conformation that is incompatible with the binding site. The
diol 30 was active and selective but did not oﬀer signiﬁcant
improvement. The triol 31, prepared as an analogue of NAM,
proved to be as active as 30 but less selective. Overall, no
signiﬁcant improvement in binding or selectivity was gained by
the introduction of more than one hydroxyl group in this series
of secondary cyclic amine derivatives.
The direct attachment of an aromatic ring to position 4 of
the pyrrolo[2,3-d]pyrimidine scaﬀold exempliﬁed by com-
pound 43 retained the potency and selectivity of the original hit
4 (Table 2). In general, compounds with para substituents in
the phenyl ring had better activity against IKKα and produced
our ﬁrst nanomolar IKKα inhibitors in 47 and 48. Although
activity against IKKβ was evident for these two compounds,
their higher potency for IKKα ensured signiﬁcant isoform
selectivity was maintained. Compounds with meta substituents
were low micromolar inhibitors of IKKα (for example 53, 56,
and 57) but were equipotent against IKKβ, apart from 55,
which was inactive against both isoforms. As with compounds
10 and 28, the inactivity of the ortho-substituted derivatives in
this series can be attributed to enforced conformational rotation
of the phenyl ring to a more orthogonal relationship with the
pyrrolo[2,3-d]pyrimidine scaﬀold, which introduces steric
clashes in the binding site. This is less pronounced with an
o-ﬂuoro substituent and, consequently, 59 had similar potency
to the unsubstituted 4-phenyl derivative 43.
Compound 48 (proprietary code SU909), with a para-primary
sulfonamide, represents the most potent IKKα inhibitor reported
to date that has signiﬁcant selectivity over IKKβ, although a
limited kinase proﬁle using 40 kinases representative of the
Scheme 4a
aReagents and conditions: (a) alkylamine, Et3N, 1,4-dioxane 200 °C
(μW) 20 min; (b) boronic acid/ester, Pd(dppf)Cl2, KOAc, H2O/
dioxane, 110 °C, 16 h.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b00484
J. Med. Chem. 2017, 60, 7043−7066
7050
Table 3. Biochemical Inhibitory Data for the 4-Substituted Pyrrolo[2,3-d]pyrimidines With and Without the 2-Amino and/or
5-Cyano groupsa
aKi values are expressed in μM units and are the result of three independent experiments.
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kinome identiﬁed oﬀ-target eﬀects (>80% inhibitory activity)
with other kinases albeit at 10 μM (Aurora A, CaMK1, CHK2,
CK1, GSK3, MEK1, and PKC: Figure 5).
To explore the role of the primary sulfonamide, the 4-methyl
sulfone analogue 49 and the secondary sulfonamides 50 and 51
were prepared. Notably, 49 and 50 had reduced potency against
IKKα, but both were more active against IKKβ, reversing the
isoform selectivity for the ﬁrst time in this series. Similarly,
when the orientation of the sulfonamide with respect to the
phenyl ring (52) was reversed, a reduction in potency against
IKKα occurred but an improvement against IKKβ was again
evident, inverting isoform selectivity.
The absence of a 5-cyano group in 48 (compound 64)
reduced activity against IKKα more than 30-fold (Table 3),
although there was a slight improvement against IKKβ. Com-
pound 65, which lacked both the 5-cyano and the 2-amino
substituent, had lower activity against both isoforms. Compound
66, without the 2-amino group but with the 5-cyano, attenuated
IKKβ activity but did not re-establish the potency against IKKα
seen for 48. The importance of the 5-cyano group for activity
against IKKα was further demonstrated by preparing analogues
of selected active N4-substituted exemplars from Table 1: removal
of the 5-cyano substituent produced inactive compounds against
both isoforms (67−69), and its replacement with other elec-
tron-withdrawing substituents such as a triﬂuoromethyl (70) or a
carboxamide (71) moiety also attenuated all IKKα inhibitory
activity (Scheme 4, Table 3). Furthermore, compound 63, which
represents the original hit compound (4) without the 5-cyano
group, was also inactive against IKKα (Table 3).
Overall, our SAR data suggest that the 5-cyano substituent is
essential for IKKα activity in this series of compounds but must
be combined with a 2-amino group to promote selectivity. To
enhance potency for IKKα, a 4-phenyl group bearing a speciﬁc
polar para-substituent appears to be crucial.
Docking Studies. To explain the general SAR proﬁle
observed with our series and to relate these to the diﬀerences
between the two IKK isoforms that our MD studies had revealed,
we performed docking studies using GOLD.36 A limited
ﬂexibility was enabled in the side chains of speciﬁc residues
that had shown signiﬁcant ﬂuctuation in the MD trajectories,
namely Asn28, Val29, and Lys44. In the co-crystal structure
of IKKβ28 that had formed the basis of our simulations,
the staurosporine analogue interacts though H-bonds with
the backbone groups of GK+1 (Glu97) and GK+3 (Cys99) in
the conserved hinge region. Initially, no attempt was made to
direct the ligands to interact speciﬁcally with the hinge region
in our docking simulations; the only requirement was to occupy
the ATP binding site. This ﬁrst docking study was performed to
ﬁnd a common binding mode that could explain the IKKα
inhibitory activity and selectivity reported for exemplars from
our two series. To explore this, compounds bearing diﬀer-
ent hydrophobic substituents were selected for their similar
potency and selectivity (e.g., 4, 9, and 43). The poses where the
2-aminopyrrolo[2,3-d]pyrimidine scaﬀold interacted with the
hinge region by H-bonds were studied in detail and compared
to similar hinge-binding protein kinase inhibitors.37 For example,
aminopurines are known to adopt two diﬀerent binding modes
in interactions with the hinge region of CDK2 via three hydro-
gen bonds.38 However, in similar poses for our compounds
in IKKα, the analogous triplet of hydrogen bonds was poorly
supported by the IKKα hinge region in terms of bond distances
and bond angles. Not surprisingly, similar poses were found
when the same compounds were docked with IKKβ, which
is due to the high isoform homology and subtle diﬀer-
ences in topography in this hinge region of the ATP binding
site. These poses could not account for the selectivity reported
in our assays and suggested that this was not the binding
mode responsible for conveying such discriminatory activity
between the isoforms. However, a binding mode where the
2-aminopyrrolo[2,3-d]pyrimidine scaﬀold interacted with the
back pocket of the IKKα active site explained the potency
and selectivity displayed by our compounds more eﬀectively.
Parts A−C of Figure 6 illustrate how compounds 4, 9, and 43
were predicted to interact with IKKα, speciﬁcally targeting the
carboxylate group of Glu61, the ammonium group of Lys44
and, most signiﬁcantly, the side chain carbonyl group of Asn28
via four H-bonds. In IKKβ, because Asn28 is involved in
a dimeric H-bond interaction with Gln48 revealed by our
simulations (Figure 3), which also changes the position of
Glu61, the triple H-bond interaction observed in IKKα is lost.
We therefore propose that the aminopyrrolo[2,3-d]pyrimidine
scaﬀold is anchored to the back of the ATP site speciﬁcally
targeting Asn28 in IKKα, which accounts for the observed
selectivity. In this orientation, the importance of the 5-cyano
group when binding with IKKα can also be explained. Exam-
ination of the trajectory from an MD simulation of 47 revealed
a water molecule present for the majority of the run that
formed a three-centered hydrogen bond bridge between the
nitrile, the side chain carboxylate of Asp102, and the backbone
NH of the same residue (Figure 6D). Overall, binding to IKKα
appears to be facilitated through four centers on the 2-amino-5-
cyanopyrrolo[2,3-d]pyrimidine scaﬀold with four residues in the
ATP binding site: Glu61, Lys44, Asn28, and Asp102. A similar
binding orientation with IKKβ is less likely because the two of
the equivalent sites are less accessible (Asn28 and Glu61), and
this would account for the lack of activity in this isoform.
Figure 5. Percent residual activity of 40 kinases challenged with compound 48 at 10 μM.
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Although the poses described for compounds 4, 9, and 43
showed no interaction with the hinge region, the equivalent
poses for the nanomolar inhibitors 47 and 48 had signif-
icant H-bond interactions with the GK+3 residue via their
p-hydroxymethyl and p-sulfonamide substituents (Figures 6D
and 7). The equivalent binding pose in IKKβ did not feature
the hydrogen bonds HB1 and HB2 due to local structural
diﬀerences observed between the kinase isoforms and could
explain the lower aﬃnity of 48 for IKKβ. Interestingly, the
presence of the methyl group in the secondary sulfonamide 50
compromised its ability to form an H-bond with the HBA
carbonyl group of GK+3 because of a steric clash with the
hinge region, thus reducing aﬃnity for IKKα. The sulfonyl
group could still interact with the NH of GK+3, which explains
Figure 7. (left) Docked pose of 48. As before, the 2-aminopyrrolo[2,3-d]pyrimidine moiety engages with the back of the ATP pocket in IKKα and
the sulfonamide group generates additional H-bonds with the main chain carbonyl and NH of GK+3 that produce nanomolar activity. (right)
Schematic representation of the proposed binding mode in the IKKα-ATP binding site showing key interactions for compound 48.
Figure 6. Docked poses of 4, 9, 43, and 47 (A−D, respectively) binding to the back of the ATP pocket in IKKα, where the 2-aminopyrrolo[2,3-
d]pyrimidine motif forms H-bonds (shown in green) with the side chain carboxylate of Glu61, the side chain ammonium group of Lys44, and the
side chain carbonyl group of Asn28. No equivalent poses were identiﬁed when these compounds were docked with IKKβ. (D) An MD simulation of
47 revealed an additional interaction with a molecule of water that formed an H-bond bridging interaction between the 5-cyano group, the side chain
of Asp102, and the backbone NH of the same residue.
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why 50 and the sulfone 49 both have similar potency against
IKKα.
The reason for both 49 and 50 also having greater inhibitory
activity against IKKβ that reverses isoform selectivity is because
the polar side chain of Asn28 in IKKβ rotates out of the back
pocket to H-bond with Gln48 (Figure 3). When 49 and 50
were docked in the IKKβ structure, they commonly adopted a
ﬂipped pose, where the 2-aminopyrrolo[2,3-d]pyrimidine
engaged with the GK+1 and +3 residues at the hinge through
H-bonding, while the sulfonyl oxygen and the 5-cyano group
H-bonded with K44 in the back pocket (Figure 8). Binding to
IKKβ by 49 and 50 in this orientation is facilitated by moving
the polar Asn28 from the immediate vicinity, creating a cleft
that can more easily accommodate the hydrophobic methyl
moiety of 49 and 50. A similar reversal of selectivity was seen
with 64, which lacks the 5-cyano substituent of 48. The drop in
potency against IKKα can be attributed to the absence of a
water-bridging H-bond interaction with Asp102 but also to
the removal of the conformationally restraining eﬀect of the
5-cyano group on the adjacent 4-phenyl ring which would
normally optimize alignment of the p-sulfonamide H-bonding
interaction with GK+3 in the hinge. The enhanced aﬃnity for
IKKβ by 64 can again be explained by the adoption of a ﬂipped
pose when binding to this isoform, which is enabled by a
more ﬂexible p-sulfonamide that can H-bond more eﬀectively
with Lys44. Just as importantly, this ﬂexibility allows the HBD
Figure 9. Eﬀect of compound 48 on (a) FCS-stimulated noncanonical and (b) TNF-α-induced canonical NF-kB activation in U2OS cells. Cells were
pretreated with 48 1 h prior to stimulation with FCS (10%) for 4 h or TNF-α (10 ng/mL) for 30 min. Whole cell lysate were prepared, separated by
SDS-PAGE, and assessed for (a) inhibition of p100 phosphorylation (Ser866/870) and (b) IkB-α and p-p65 (Ser536) status. (c) Blots were
quantiﬁed, and the IC50 value for inhibition of p100 phosphorylation was determined (48 IC50 = 5.8 μM). The results are representative of three
independent experiments.
Figure 8. (left) Docked pose of 50 in IKKβ. Unlike IKKα, the aminopyrrolo[2,3-d]pyrimidine moiety has ﬂipped and H-bonds to GK+1 and GK+3.
The rotation of Asn28 out of the pocket to H-bond with Glu48 allows the sulfonyl group to H-bond to Lys44 and accommodates the lipophilic
methyl group in the cleft opened up by this rotation. (right) Schematic representation of the proposed binding mode in the IKKβ-ATP binding site
showing key interactions for compound 50.
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of the sulfonamide group to access the less accessible Glu41 at
the back of IKKβ pocket.
In summary, in line with our SAR data and the hypothesis
derived from our MD simulation studies, we suggest that
nanomolar potency against IKKα with selectivity over IKKβ
can be accomplished by having molecules that can bind to the
hinge region of the ATP binding site and to the Asn28 residue
at the back of the pocket that is available in IKKα but not
in IKKβ (Figure 8). Furthermore, inhibitory potency against
IKKα can be enhanced when compounds can form H-bonding
interactions with the three residues in the back pocket (Glu41,
Lys44, Asn28) and the GK+3 and Asp102 residues in the
hinge.
Demonstrating IKKα Activity and Selectivity Is
Recapitulated in Cells. The objective of the cell-based
assessment was to characterize whether the two most active
compounds against IKKα (47 and 48) recapitulated their
activity in a cellular environment. IKKα but not IKKβ plays a
role in the regulation of the noncanonical NF-κB cascade
which initially involves phosphorylation of p100, followed by
p100 processing to p52 to regulate a number of genes that
contribute to and promote cellular growth.39 More recent
studies have shown that overactivation of the noncanonical
NF-κB pathway in a variety of cellular settings, e.g., prostate19,21
and pancreas,25−27 is inherently associated with cell survival and
proliferation. The U2OS osteosarcoma cell line is representa-
tive of these proliferative characteristics and is dependent on
constitutively activated IKKα signaling;40 it was therefore
selected as the system to demonstrate perturbation of IKKα
activity in the cellular environment.
Pretreatment of U2OS cells with increasing concentration of
48 and 47 resulted in concentration-dependent inhibition of
FCS-stimulated phosphorylation of p100 (Figures 9a and 10a).
The IC50 values for 48 and 47 were calculated as 8.8 and
13.9 μM, respectively. Two IKKβ-dependent readouts were
selected to assess selectivity over IKKβ. First, TNFα stimulates
IκBα degradation through activation of IKKβ and if IKKβ is
inhibited, then a band corresponding to the IκBα protein
should be evident by Western analysis. Second, IKKβ phos-
phorylates p65 on Ser536, which can also be assessed by
Western blot analysis. Only at the highest concentration
(100 μM) of 48 was IκBα degradation and p65 (Ser536) phos-
phorylation inhibited (Figure 9b). Even at this high concentra-
tion, these eﬀects were not apparent following pretreatment
with 47 (Figure 10b).
To provide further evidence for cellular activity, mouse
embryonic ﬁbroblasts lacking the IKKβ kinase subunit were
utilized to investigate the potency of both compounds against
agonist-stimulated IKKα-regulated NF-κB transcriptional acti-
vation. Cells were infected with an adenovirus encoding an
NF-κB-luciferase promoter gene. NF-κB transcriptional activity
driven by IKKα was stimulated speciﬁcally using IL-1β,41 and
the ability of the compounds to inhibit this response was assessed.
At maximal concentrations of 50−100 μM, 48 abolished tran-
scriptional activity compared to 47 which inhibited activity by
approximately 81% (% stim: Il-1β+DMSO = 100%, 48+Il-1β =
−40.9 ± 4.6%, 47+IL-1β = 18.79 ± 7.2%, both **P < 0.01)
(Table 4). Both 47 and 48 demonstrated concentration-depen-
dent inhibitory eﬀects on FCS-induced phosphorylation of
p100 by IKKα. As IKKα plays a lesser role in the canonical
NF-κB cascade,42 particularly the rapid and transient stimulated
degradation of IκBα, selective IKKα inhibitors should not aﬀect
TNF-α induced IκBα degradation and p65 phosphorylation.
Compound 47 did not aﬀect either agonist stimulated IκBα
degradation or p65 phosphorylation, while 48 only had a small
eﬀect on both markers at the highest concentration tested
(100 μM). Taken together, these data demonstrate that 47 and
48 are the ﬁrst examples of IKKα-selective compounds that
inhibit agonist-stimulated NF-κB signaling of the noncanonical
pathway at much lower concentrations than the canonical
pathway.
Figure 10. Eﬀect of compound 47 on (a) FCS-stimulated noncanonical and (b) TNF-α-induced canonical NF-kB activation in U2OS cells. Cells
were pretreated with 47 1 h prior to stimulation with FCS (10%) for 4 h or TNF-α (10 ng/mL) for 30 min. Whole cell lysate were prepared,
separated by SDS-PAGE, and assessed for (a) inhibition of p100 phosphorylation (Ser866/870) and (b) IkB-α and p-p65 (Ser536) status. (c) Blots
were quantiﬁed, and the IC50 value for inhibition of p-p100 was determined (47 IC50 = 19.1 μM). The results are representative of three independent
experiments.
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■ CONCLUSION
There are many reported inhibitors of IKKβ, primarily because
it was considered a viable target in inﬂammatory disease. Design-
ing inhibitors of IKKα that are selective over IKKβ has to this
date not been reported despite the former isoform now being
recognized as a potential target in a number of cancers. One reason
for this is the high sequence-homology in the ATP-binding site of
the two isoforms and the absence of any high-resolution crystal
structure of IKKα to guide structure-based inhibitor design.
By employing molecular dynamics simulations on a homol-
ogy model of IKKα based on IKKβ, we identiﬁed key dynamic
diﬀerences at the ATP-binding site and exploited these to
design the ﬁrst selective inhibitors of IKKα. Our compounds
demonstrated target engagement with IKKα-related pharma-
codynamic markers and nonengagement with IKKβ markers in
cells. These compounds therefore represent the ﬁrst chemical
tools that can be used to further characterize the role of IKKα
in cellular signaling, to dissect this from the very similar IKKβ
isoform and to validate IKKα in its own right as a target in
cancers, such as prostate, breast, and pancreatic cancer.
The discovery of a 2-aminopyrrolo[2,3-d]pyrimidine chemical
series also provides valuable information with respect to SAR
for IKKα inhibitory activity. Substituents at position 4 of the
pyrrolo[2,3-d]pyrimidine scaﬀold allowed for diversiﬁcation,
with IKKα selectivity achievable through the introduction
of groups that speciﬁcally target residues in its binding site.
However, further signiﬁcant improvements in activity through
aliphatic 4-amino substituents appear to be unlikely. Modifying
the 4-phenyl substituent oﬀers a more promising route toward
generating compounds with improved activity and selectivity.
Using this strategy, we are currently developing more potent
IKKα-inhibitors that display functional outputs in a number of
cell lines, all of which will be reported in due course.
■ EXPERIMENTAL SECTION
IKKα Homology Model. Building a homology model of IKKα: the
kinase domain of IKKβ (chain B, residues 1−309, PDB entry 4KIK.28
was used as a template to build the kinase domain of IKKα, keeping
the inhibitor (KSA700 in the pdb ﬁle) and waters found within 6 Å of
the protein−inhibitor complex. The residue alignment (Figure Mod1)
and homology building were performed using Discovery Studio 3.1
(Accelrys Inc., San Diego, USA) after missing residues D174, Q175,
and G176 were added in an extended conformation.
Both IKK kinase domains were subjected to molecular dynamics
using the AMBER12 simulation software. The inhibitor present
(residue name KSA700) was kept and parametrized using ante-
chamber and charges calculated and ﬁtted using the AM1-BCC
scheme. The two systems were placed in a periodic octahedral box and
solvated with TIP3P water with outer edges 6 Å in each direction from
the closest solute atom. The systems were then neutralized and
physiological salt conditions applied (∼150 mM) by adding 24 Cl−
and 29 Na+ ions to the IKKα system and 24 Cl− and 30 Na+ ions to
the IKKβ system. The AMBER ﬀ12SB was applied to all protein
atoms, while gaﬀ was used for the ligand. Parameters for the
phosphoserine residues were taken from Craft and Legge.43 Before the
MD production phase, minimization and equilibration (to reach
310 K) were performed in two stages as described.44 The NPT
ensemble was used at 310 K until the systems had stabilized for at least
20 ns (50 and 100 ns simulation time for IKKβ and IKKα, respec-
tively). All MD steps used the SHAKE algorithm45 with a 2 fs time-
step and a 10 Å cutoﬀ for long-range electrostatic interactions.
An average structure was generated (using ptraj within the AMBER
suite) for the last 21 ns (IKKα) or 26 ns (IKKβ) and subsequently
minimized in three steps, with the solvent, ions, and hydrogen atoms
initially minimized while the protein and inhibitor were restrained by
100 kcal mol−1 Å−2. The restraint was then removed from the protein
side chain atoms, and ﬁnally the whole system was allowed to mini-
mize until a derivative of 0.1 kcal mol−1 Å−2 was achieved. These
structures were then utilized for further docking studies with the
GOLD software.
General Experimental. Solvents (reagent grade or better) were
purchased from Sigma-Aldrich or Fischer Scientiﬁc. Anhydrous sol-
vents where purchased from Sigma-Aldrich. Deuterated solvents were
purchased from Sigma-Aldrich. Chemicals (95% purity or above) were
purchased from Acros Organics, Alfa Aesar, Apollo, Fluorochem, or
Sigma-Aldrich. Solvents and chemicals were used as received without
further puriﬁcation or treatment.
Oxygen- or moisture-sensitive reactions were carried out under a
nitrogen atmosphere.
Microwave reactions were performed with a Biotage Initiator
system. High absorbance was selected for polar solvents and normal
absorbance was selected for nonpolar solvents.
The progress of the reactions was monitored on Merck 60F254
TLC plates. Spots were visualized by irradiation with ultraviolet light
(254/366 nm) or KMnO4, ninhydrin, or phosphomolibdic acid (PMA)
TLC stains.
Column chromatography was performed with a Biotage SP4
system; cartridge size and eluent speciﬁed in the corresponding experi-
ments (% is referring to the most polar solvent in the mixture), using
silica gel as the stationary phase (particle size 0.040−0.063 mm, Merck
or Fisher Scientiﬁc).
Speciﬁc rotations were measured in a PerkinElmer polarimeter 341
apparatus at 20 °C and a wavelength of 589 nm (sodium D line) in
DMSO UV spectrophotometric analysis grade.
1H and 13C NMR data were recorded on either a JEOL ECX-400
(400 MHz) or Bruker Avance3/DPX400 (400 MHz) spectrometers at
400.0 and 100.6 MHz, respectively. Chemical shifts (δ) are expressed
in parts per million (ppm) coupling constants (J) are in hertz (Hz).
Chemical shifts (δ) are reported relative to TMS (δ = 0 ppm) and/or
referenced to the solvent in which they were measured. All measure-
ments were carried out at 298 K (except when stated). Abbreviations
used in the description of NMR data are as follows: app, apparent;
s, singlet; bs, broad singlet; d, doublet; t, triplet; q, quartet; p, pentuplet;
m, multiplet.
HR-MS was conducted using a Thermo Scientiﬁc Exactive Orbitrap
mass analyzer. LR-MS was conducted using a ThermoQuest Finnigan
LCQ Duo instrument. GC-MS was conducted using a ThermoQuest
Finnigan Polaris Q instrument.
Final compounds tested in the kinase inhibition assay possessed
a purity of ≥95% by HPLC analysis (unless stated otherwise) con-
ducted using an Agilent Technologies 1220 series system (methods A,
B, C, and D). Column: Agilent Eclipse XDB C18 4.6 mm ID ×
250 mm (5 μm) 80 Å. Flow rate: 1 mL/min. Detector: 254 nm.
Sample volume: 10 μL. Mobile phase: (method A) 15% MeCN
in H2O (3 min), 15−90% MeCN in H2O (12 min) followed by
Table 4. Il-1β-Stimulated NF-κB Transcriptional Activation
in IKKα−/− MEFsa
treatment % stimulation
IL-1β + DMSO 100
Il-1β+47 (100 μM) −40.9 ± 4.6**
Il-1β+48 (100 μM) 18.79 ± 7.2**
aIKKβ−/− MEFs infected with Adv.NF-kB.luc were grown to near
conﬂuency and rendered quiescent by serum deprivation for 24 h.
Cells were then pre-treated for 1 h with increasing concentrations of
compounds 48 or 47 prior to stimulation with IL-1β (10 ng/mL) for a
further 6 h. Cells were assayed for NF-κB-linked luciferase reporter
activity, as outlined in the methods section. Values (RLUs) were
collated and converted to percentage stimulation (of positive control =
IL-1β + DMSO). Each value represents the mean ± SEM from at least
four independent experiments, and data was quantiﬁed using one way
ANOVA, with Dunnett’s post-test. *P < 0.05. 88P < 0.01 compared to
IL-1β+DMSO alone.
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equilibration/blank run; (method B) 5% MeCN in H2O (3 min),
5−100% MeCN in H2O (14 min), 100% MeCN in H2O (5 min),
100−5% MeCN in H2O (5 min), 5% MeCN in H2O (5 min) followed
by blank run; (method C) 5% MeCN + 5 mM NH4Ac in H2O +
5 mM NH4Ac (3 min), 5−100% MeCN + 5 mM NH4Ac in
H2O + 5 mM NH4Ac (14 min), 100% MeCN + 5 mM NH4Ac in
H2O + 5 mM NH4Ac (5 min), 100−5% MeCN in H2O (5 min), 5%
MeCN + 5 mM NH4Ac in H2O + 5 mM NH4Ac (5 min) followed by
blank run. Method D was conducted in a Dionex UltiMate 3000 LC
system. Column: ACE 3 C8 3 mm ID × 50 mm. Mobile phase:
5−95% MeCN + 0.1% HCO2H in H2O + 0.1% HCO2H (24 min),
95−5% MeCN + 0.1% HCO2H in H2O + 0.1% HCO2H (1 min), 5%
MeCN + 0.1% HCO2H in H2O + 0.1% HCO2H (5 min). Flow rate:
0.4 mL/min. Detector: 254 nm. Sample volume: 10 μL.
2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-car-
bonitrile (1). Methyl formate (18.0 mL, 17.48 g, 291.4 mmol) in
toluene (8 mL) was added at 0 °C to a stirred suspension of NaOMe
(14.30 g, 264.9 mmol) in toluene (200 mL). This was followed by
dropwise addition of chloroacetonitrile (16.8 mL, 20.00 g, 264.9 mmol)
in toluene (60 mL) over 1 h. The reaction mixture was stirred for 3 h
followed by addition of H2O (150 mL). The organic layer was
separated, and the aqueous layer was acidiﬁed to pH 5 using 6 M HCl
and subsequently extracted with EtOAc (3 × 100 mL). The organic
layers were combined and dried over MgSO4 and concentrated in
vacuo (40 °C, 70 mbar). The dark residue was suspended in H2O
(60 mL) and added to a solution of NaOAc (16.39 g, 199.8 mmol)
and 2,6-diaminopyrimidin-4(3H)-one (12.00 g, 95.2 mmol) in H2O
(200 mL) (previously stirred at 100 °C until complete dissolution).
The reaction was reﬂuxed for 16 h. After cooling to room temperature,
the suspension was ﬁltered and washed with H2O (2 × 20 mL),
acetone (2 × 10 mL), and Et2O (2 × 40 mL) to yield 1 (10.11 g, 60%)
as a light-tan solid. 1H NMR (400 MHz, DMSO-d6) δ: 6.37 (bs, 2H),
7.58 (s, 1H), 10.70 (bs, 1H), 11.95 (bs, 1H). 13C NMR (100 MHz,
DMSO-d6) δ: 86.0, 99.2, 116.3, 128.2, 158.0, 152.1, 154.2. 3
N-(7-Acetyl-5-cyano-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-
pyrimidin-2- yl)acetamide (2). A suspension of 1 (1.18 g, 6.74 mmol)
in acetic anhydride (18 mL) and dry DMF (10 mL) was heated at
150 °C for 4 h. Solvents were evaporated in vacuo, and the residue was
triturated with Et2O (2 × 10 mL) to yield 2 (1.65 g, 95%) as a brown
solid. 1H NMR (400 MHz, DMSO-d6) δ: 2.22 (s, 3H), 2.86 (s, 3H),
8.41 (s, 1H), 11.73 (bs, 1H), 12.20 (bs, 1H). 13C NMR (100 MHz,
DMSO-d6) δ: 24.5, 26.0, 90.5, 105.1, 114.2, 129.8, 148.9, 149.3, 155.7,
168.5, 174.4.
N-(5-Cyano-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-
pivalamide (3). 1 (7.33 g, 28.30 mmol) was stirred in dry pyridine
(60 mL) at 60 °C for 1 h. Upon formation of a homogeneous sus-
pension, the mixture was cooled to 0 °C and treated dropwise with
pivaloyl chloride (10.5 mL, 10.23 g, 84.87 mmol). The suspension was
then stirred at 85 °C for 2 h. After cooling to room temperature, the
resulting suspension was neutralized with 33% ammonia in H2O and
left to stand at 4 °C for 16 h. The suspension was ﬁltered oﬀ, washed
with H2O (10 mL), dried, and then triturated with Et2O (2 × 10 mL)
to aﬀord 3 (6.97 g, 64%) as a pale-brown solid. 1H NMR (400 MHz,
DMSO-d6) δ: 1.25 (s, 9H), 7.93 (s, 1H), 11.00 (bs, 1H), 12.11
(bs, 1H) and 12.65 (bs, 1H). 13C NMR (100 MHz, DMSO-d6) δ:
27.0, 40.7, 86.9, 103.7, 115.9, 130.9, 149.1, 149.1, 156.4, 181.7.
2-Amino-4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile (4).
POCl3 (5.2 mL, 8.57 g, 55.9 mmol) was added dropwise to a
suspension of 2 (1.61 g, 6.21 mmol) and N,N-dimethylaniline (1.2 mL,
1.13 g, 9.32 mmol) in dry MeCN (10 mL). The reaction mixture was
heated at 100 °C for 6 h. After cooling to room temperature, the
mixture was placed in an ice bath and neutralized with saturated
aqueous Na2CO3. The suspension was ﬁltered oﬀ, washed with H2O
(10 mL), dried, and then triturated with Et2O (2 × 10 mL) to aﬀord 6
(1.44 g) as a brown solid. Chromatographic puriﬁcation (manual
column, solvent system: MeOH/EtOAc; gradient 0% 50 mL, 0−25%
200 mL, 25% 100 mL) yielded a pure analytical sample of 6. 1H NMR
(400 MHz, DMSO-d6) δ: 6.95 (bs, 2H), 8.11 (s, 1H), 12.52 (bs, 1H).
13C NMR (100 MHz, DMSO-d6) δ: 83.5, 106.5, 115.4, 134.5, 151.5,
155.0, 160.8. HRMS (ESI) calculated for for C7H5N5Cl [M + H]
+
194.0228, found 194.0229. HPLC tR = 5.56 min (method D).
N-(4-Chloro-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide
(5). A suspension of 3 (6.82 g, 26.31 mmol), N,N-dimethylaniline
(14 mL, 13.39 g, 110.48 mmol), and triethylbenzylammonium
chloride (2.93 g, 13.15 mmol) in dry MeCN (100 mL) was treated
dropwise with POCl3 (24.5 mL, 40.33 g, 263.05 mmol). The reaction
mixture was reﬂuxed for 1 h, allowed to cool down, and concentrated
in vacuo. The resulting dark oil was cautiously treated with ice and
was set to pH = 5 using 33% ammonia in H2O. The aqueous layer
was extracted with EtOAc (4 × 100 mL), and the combined organic
layers were dried over MgSO4 and concentrated in vacuo. The residue
was triturated with Et2O (3 × 30 mL), MeOH (2 × 20 mL), and Et2O
(2 × 20 mL) to give 5 (2.56 g, 35%) as a light-tan solid. 1H NMR
(400 MHz, DMSO-d6) δ: 1.22 (s, 9H), 8.50 (s, 1H), 10.27 (bs, 1H),
13.35 (bs, 1H). 13C NMR (100 MHz, DMSO-d6) δ: 27.4, 40.3, 84.1,
111.8, 115.1, 138.2, 151.4, 153.5, 153.8, 176.5.
2,4-Diamino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile (6). Pyr-
imidine-2,4,6-triamine (800 mg, 6.39 mmol) was added to a solution
of NaOAc (1.10 g, 13.43 mmol) in distilled water (20 mL) and stirred
at 50 °C until near total dissolution. A solution of 2-chloro-3-oxo-
propanenitrile (794 mg, 7.67 mmol) in H2O (10 mL) was added
dropwise over 1 h to the reaction mixture, then stirred 16 h at 50 °C,
and subsequently, the mixture was reﬂuxed for 1 h. After cooling to
room temperature, the reaction was cooled to 0 °C for 2 h. The
obtained black solid was boiled in MeOH (4 mL) and washed with hot
MeOH (2 × 4 mL). The remaining solid was reﬂuxed in H2O (5 mL)
and washed with hot H2O (5 mL) to yield 34 (91 mg, 8%) as a dark
solid. 1H NMR (400 MHz, DMSO-d6) δ: 5.89 (bs, 2H), 6.17 (bs, 2H),
7.68 (s, 1H), 11.82 (bs, 1H). 13C NMR (100 MHz, DMSO-d6) δ: 82.5,
94.6, 117.4, 129.4, 154.3, 157.8, 161.7. HRMS (ESI) calculated for for
C7H5N6 [M − H]− 173.0581, found 173.0581.
2-Amino-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-car-
bonitrile (7) (Procedure A*). 5 (100 mg, 0.52 mmol), methylamine
(8 M solution in EtOH) (53 mg, 0.20 mL, 1.70 mmol), and
N,N-dimethylaniline (94 mg, 0.1 mL, 0.77 mmol) were suspended in
dry 1,4-dioxane (2 mL) and heated for 20 min at 200 °C in the
microwave reactor. After cooling to room temperature, the reaction
mixture was suspended in MeOH, adsorbed on silica gel, and
concentrated in vacuo*. Chromatographic puriﬁcation (Biotage SP4,
10 g cartridge, solvent system: MeOH/EtOAc; gradient 0% 4CV,
0−5% 10CV, 5% 4CV) yielded 7 (20 mg, 21%) as a pale-cream solid.
1H NMR (400 MHz, DMSO-d6) δ: 2.92 (d, J = 4.6 Hz, 3H), 5.94
(bs, 2H), 6.05 (q, J = 4.6 Hz, 1H), 7.67 (s, 1H), 11.73 (bs, 1H).
13C NMR (100 MHz, DMSO-d6) δ: 28.3, 82.3, 94.8, 117.4, 129.1,
153.6, 157.3, 161.5. HRMS (ESI) calculated for for C8H9N6 [M + H]
+
189.0883, found 189.0883. HPLC tR = 4.09 min (method A).
2-Amino-4-((cyclopropylmethyl)amino)-7H-pyrrolo[2,3-d]-
pyrimidine-5-carbonitrile (8) (Procedure B). 5 (0.109 g, 0.39 mmol)
and cyclopropanemethylamine (0.105 mL, 1.21 mmol) in 1,4-dioxane
(2 mL, anhydrous) in a microwave vial was heated to 200 °C for
20 min. The resulting solution was then diluted with EtOH (6 mL)
and KOH (2 pellets) was added and the reaction mixture was heated
to 90 °C for 20 h. The reaction mixture was then concentrated under
reduced pressure, the residue was suspended in water, and the mixture
was pH adjusted to pH 5.5, extracted into EtOAc, dried over MgSO4,
and concentrated under reduced pressure. The resulting solid was
triturated with Et2O and ﬁltered to aﬀord the title compound as an oﬀ-
white solid (0.032 g, 0.14 mmol, 36%). 1H NMR (DMSO-d6): δ 0.29
(m, 2H), 0.44 (m, 2H), 1.16 (m, 1H), 3.32 (m, 2H), 5.90 (t, J =
5.4 Hz, 1H), 5.96 (s, 2H), 7.69 (s, 1H), 11.82 (br s, 1H). HRMS (ESI)
calculated for C11H13N6 229.1194, found 229.1196.
2-Amino-4-(cyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-
carbonitrile (9). Prepared according to procedure A. Chromatographic
puriﬁcation (Biotage SP4, 10 g cartridge, solvent system: MeOH/
EtOAc; gradient 0% 4CV, 0−2% 12CV) yielded 11 (35 mg, 26%) as a
pale-cream solid. 1H NMR (400 MHz, DMSO-d6) δ: 1.22−1.28
(m, 1H), 1.30−1.37 (m, 4H), 1.54−1.57 (m, 1H), 1.67−1.70 (m, 2H),
1.91−1.93 (m, 2H), 4.01−4.08 (m, 1H), 5.32 (d, J = 8.0 Hz, 1H),
5.92 (bs, 2H), 7.66 (s, 1H), 11.80 (bs, 1H). 13C NMR (100 MHz,
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DMSO-d6) δ: 24.8, 25.7, 32.8, 48.3, 81.8, 94.6, 117.7, 128.7, 153.6,
156.0, 161.6. HRMS (ESI) calculated for for C13H17N6 [M + H]
+
257.1509, found 257.1504. HPLC tR = 11.09 min (method A).
2-Amino-4-(cyclohexylmethylamino)-7H-pyrrolo[2,3-d]-
pyrimidine-5-carbonitrile (10). Prepared according to procedure A.
Chromatographic puriﬁcation (Biotage SP4, 10 g cartridge, solvent
system: EtOAc/Hex; gradient 25% 4CV, 25−100% 10CV, 100% 6CV)
yielded 9 (27 mg, 19%) as a pale-cream solid. 1H NMR (400 MHz,
DMSO-d6) δ: 0.91−1.01 (m, 2H), 1.13−1.23 (m, 3H), 1.54−1.65
(m, 2H), 1.68−1.74 (m, 4H), 3.32 (m, 2H), 5.75 (t, J = 5.7 Hz, 1H),
5.94 (bs, 2H), 7.68 (s, 1H), 11.82 (bs, 1H). 13C NMR (100 MHz,
DMSO-d6) δ: 26.0, 26.7, 31.0, 38.0, 46.4, 82.0, 94.8, 117.6, 128.9,
153.6, 157.0, 161.6. HRMS (ESI) calculated for for C14H17N6
[M −H]− 269.1520, found 269.1519. HPLC tR = 11.83 min (method A).
2-Amino-4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-car-
bonitrile (11). Prepared according to procedure A. Chromatographic
puriﬁcation (Biotage SP4, 10 g cartridge, solvent system: EtOAc/Hex;
gradient 25% 4CV, 25−100% 10CV, 100% 6CV) yielded 11 (37 mg,
29%) as a pale-yellow solid. 1H NMR (400 MHz, DMSO-d6) δ: 6.20
(bs, 2H), 7.00−7.04 (m, 1H), 7.30−7.33 (m, 2H), 7.68−7.70 (m, 2H),
7.68−7.70 (m, 1H), 8.03 (bs, 1H), 11.86 (bs, 1H). 13C NMR
(100 MHz, DMSO-d6) δ: 82.8, 96.0, 117.3, 120.8, 122.8, 129.2, 130.3,
140.5, 154.5, 154.6, 161.2. HRMS (ESI) calculated for for C13H9N6
[M − H]− 249.0894, found 249.0891. HPLC tR = 9.85 min (method A).
4-((2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-
benzoic acid (12). 5 (0.103 g, 0.37 mmol) and methyl-4-amino-
benzoate (0.166 g, 1.1 mmol) in 1,4-dioxane (2 mL, anhydrous) in a
2−5 mL microwave vial was heated to 200 °C for 20 min. Ethanol
(4 mL) was added to the reaction mixture and KOH (1 pellet) was
added and the mixture heated to 80 °C for 24 h. The reaction mixture
was concentrated under reduced pressure, water was added, and the
mixture was pH adjusted to pH 5 with acid. The resulting white
precipitate was ﬁltered under reduced pressure and dried in an oven to
aﬀord the title compound as a white solid (0.0135 g, 0.05 mmol, 13%).
1H NMR (DMSO-d6): δ 6.33 (br s, 2H), 7.88 (m, 5H), 8.57 (s, 1H),
12.08 (br s, 1H), 12.61 (br s, 1H). HRMS (ESI) calculated for
C14H11O2N6 295.0938, found 295.0938.
4-((2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-
benzenesulfonamide (13). Prepared according to procedure B. The
remaining solid was triturated with cold H2O (2 × 2 mL), ﬁltered, dried,
and then triturated with Et2O (2 × 3 mL) to yield 13 as an oﬀ-white
solid (0.0096 g, 0.03 mmol, 8%). 1H NMR (DMSO-d6): δ 6.63 (br s,
2H), 7.55 (br s, 2H), 7.80 (m, 4H), 8.13 (s, 1H), 12.38 (br s, 1H).
HRMS (ESI) calculated for C13H12O2N7S 330.0768, found 330.0768.
2-Amino-4-(benzylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-car-
bonitrile (14). Prepared according to procedure A. Chromatographic
puriﬁcation (Biotage SP4, 10 g cartridge, solvent system: EtOAc/Hex;
gradient 80% 4CV, 80−100% 4CV, 100% 13 4C,; then MeOH/
EtOAc, gradien: 0−10% 4CV) yielded 14 (53 mg, 39%) as a light-tan
solid. 1H NMR (400 MHz, DMSO-d6) δ: 4.69 (d, J = 5.9 Hz, 1H),
5.96 (bs, 2H), 6.48 (t, J = 5.9 Hz, 1H), 7.23−7.38 (m, 5H), 7.71
(s, 1H), 11.85 (bs, 1H). 13C NMR (100 MHz, DMSO-d6) δ: 43.7,
82.2, 94.6, 117.4, 127.2, 127.9, 128.89, 129.4, 140.7, 153.9, 156.6,
161.5. HRMS (ESI) calculated for C14H11N6 [M − H]− 263.10507,
found 263.10489. HPLC tR = 10.05 min (method A).
2-Amino-4-(2-morpholinoethylamino)-7H-pyrrolo[2,3-d]-
pyrimidine-5-carbonitrile (15). Prepared according to procedure A.
Chromatographic puriﬁcation (Biotage SP4, 10 g cartridge, solvent
system: MeOH/EtOAc; gradient 0% 4CV, 0−10% 12CV, 10% 6CV)
yielded 15 (23 mg, 31%) as a white solid. 1H NMR (400 MHz,
DMSO-d6) δ: 2.42−2.46 (m, 4H), 2.54−2.57 (m, 2H), 3.50−3.54
(m, 2H), 3.61−3.63 (m, 4H), 5.98 (bs, 2H), 6.17 (t, J = 4.7 Hz, 1H),
7.69 (s, 1H), 11.82 (bs, 1H). 13C NMR (100 MHz, DMSO-d6) δ: 36.9,
53.5, 56.7, 66.8, 82.1, 94.8, 117.4, 128.9, 153.6, 156.5, 161.7. HRMS
(ESI) calculated for C13H16ON7 [ M− H]− 286.1422, found 286.1421.
HPLC tR = 3.25 min (method B).
2-Amino-4-(2-hydroxyethylamino)-7H-pyrrolo[2,3-d]pyrimidine-
5-carbonitrile (16). Prepared according to procedure A. Chromato-
graphic puriﬁcation (Biotage SP4, 10 g cartridge, solvent system:
MeOH/EtOAc; gradient 0% 6CV, 0−10% 12CV, 10% 6CV) yielded
16 (16 mg, 24%) as a white solid. 1H NMR (400 MHz, DMSO-d6)
δ: 3.52−3.58 (m, 4H), 4.86 (t, J = 4.6 Hz, 1H), 5.89 (t, J = 5.1 Hz, 1H),
5.97 (bs, 2H), 7.29 (s, 1H), 11.83 (bs, 1H). 13C NMR (100 MHz,
DMSO-d6) δ: 42.9, 60.2, 82.0, 94.6, 117.3, 129.0, 153.5, 156.7, 161.3.
HRMS (ESI) calculated for C9H10ON6 [M + H]
+ 219.0989, found
219.0987. HPLC tR = 2.79 min (method A).
2-Amino-4-(piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-car-
bonitrile (17). Prepared according to procedure B. The remaining
solid was triturated with cold H2O (2 × 2 mL), ﬁltered, dried, and
then triturated with Et2O (2 × 3 mL) to yield 17 (43 mg, 49%) as a
pale-yellow solid. 1H NMR (400 MHz, DMSO-d6) δ: 1.62−1.65
(m, 6H), 3.52−3.57 (m, 4H), 6.02 (bs, 2H), 7.83 (s, 1H), 11.95
(bs, 1H). 13C NMR (100 MHz, DMSO-d6) δ: 24.7, 26.00, 49.2, 84.1,
95.9, 118.2, 131.1, 155.6, 159.8, 160.6. HRMS (ESI) calculated for
C12H16N6 [M + H]
+ 243.1353, found 243.1349. HPLC tR = 9.63 min
(method A).
1-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-
4-sulfonamide (18). 5 (105 mg, 0.38 mmol), piperidine-4-sulfonic
acid amide hydrochloride (139 mg, 0.85 mmol) and triethylamine
(0.16 mL, 1.15 mmol) in 1,4-dioxane (2.5 mL) was degassed under
nitrogen prior to being irradiated with microwaves at 200 °C for
20 min. Once cooled to room temperature, the reaction mixture was
diluted with EtOH (8 mL) and KOH (2 pellets) were added and the
reaction mixture was heated to 90 °C for 22 h. The reaction mixture
was then concentrated under reduced pressure, water was added, and
the mixture was adjusted to pH 5.5 with 1 M HCl. This was then
extracted into EtOAc, and the organics were dried over MgSO4, ﬁltered,
and concentrated under reduced pressure. The crude material was
then puriﬁed by column chromatography (using 100% hexane−100%
EtOAc as eluent) to aﬀord the title compound 18 as a white solid
(26.1 mg, 0.08 mmol, 21%). 1H NMR (DMSO-d6): δ 1.73 (m, 2H),
2.09 (d, J = 8.4 Hz, 2H), 3.00 (t, J = 9.4 Hz, 2H), 3.11 (m, 1H), 4.32
(d, J = 10.4 Hz, 2H), 6.06 (br s, 2H), 6.80 (br s, 2H), 7.85 (s, 1H),
11.99 (br s, 1H). HRMS (ESI) calculated for C12H14O2N7S 320.0935,
found 320.0938.
2-Amino-4-morpholino-7H-pyrrolo[2,3-d]pyrimidine-5-carboni-
trile (19). Prepared according to procedure A. Chromatographic
puriﬁcation (Biotage SP4, 10 g cartridge, solvent system: MeOH/
EtOAc; gradient 0% 4CV, 0−2% 10CV) yielded 21 (40 mg, 32%) as a
pale-cream solid. 1H NMR (400 MHz, DMSO-d6) δ: 3.53−3.55
(m, 4H), 3.73−3.75 (m, 4H), 6.13 (bs, 2H), 7.88 (s, 1H), 11.78
(bs, 1H). 13C NMR (100 MHz, DMSO-d6) δ: 49.0, 66.5, 83.7, 96.2,
118.3, 131.5, 155.7, 159.8, 160.7. HRMS (ESI) calculated for C11H11ON6
[M − H]− 243.0999, found 243.0997. HPLC tR = 6.84 min (method A).
2-Amino-4-(4-methylpiperazin-1-yl)-7H-pyrrolo[2,3-d]-
pyrimidine-5-carbonitrile (20). Prepared according to procedure B.
The remaining solid was triturated with cold H2O (2 × 2 mL), ﬁltered,
dried, and then triturated with Et2O (2 × 3 mL) to yield 20 (63 mg,
68%) as a pale-yellow solid. 1H NMR (400 MHz, DMSO-d6) δ: 2.23
(s, 3H), 2.45 (app t, J = 4.8 Hz, 4H), 3.55 (app t, J = 4.8 Hz, 4H), 6.09
(bs, 2H), 7.86 (s, 1H), 11.96 (bs, 1H). 13C NMR (100 MHz, DMSO-d6)
δ: 27.5, 48.0, 54.9, 83.8, 95.9, 118.1, 131.3, 155.6, 159.5, 160.5. HRMS
(ESI) calculated for C12H14N7 [M − H]− 256.1316, found 256.1317.
HPLC tR = 1.75 min (method C).
2-Amino-4-(4-phenylpiperazin-1-yl)-7H-pyrrolo[2,3-d]-
pyrimidine-5-carbonitrile (21). Prepared according to procedure B.
The remaining solid was triturated with cold H2O (2 × 2 mL), ﬁltered,
dried, and then triturated with Et2O (2 × 3 mL) to yield 21 (83 mg,
85%) as a pale-yellow solid. 1H NMR (400 MHz, DMSO-d6) δ: 3.29
(app t, J = 4.8 Hz, 4H), 3.71 (app t, J = 4.8 Hz, 4H), 6.06 (bs, 2H),
6.79−6.83 (m, 1H), 6.99−7.01 (m, 2H), 7.22−7.24 (m, 2H), 7.87
(s, 1H), 12.04 (bs, 1H). 13C NMR (100 MHz, DMSO-d6) δ: 48.3,
48.7, 83.2, 96.7, 116.1, 118.7, 119.7, 129.6, 132.9, 151.5, 156.5, 159.7,
160.5. HRMS (ESI) calculated for C17H18N7 [M + H]
+ 320.1618,
found 320.1614. HPLC tR = 11.09 min (method A).
2-Amino-4-(4-(2-hydroxyethyl)piperazin-1-yl)-7H-pyrrolo[2,3-d]-
pyrimidine-5-carbonitrile (22). Prepared according to procedure B.
The remaining solid was suspended in MeOH, adsorbed on silica gel,
and concentrated in vacuo. Chromatographic puriﬁcation (Biotage
SP4, 10 g cartridge, solvent system: 5% NH4OH in MeOH/EtOAc;
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gradient 10% 4CV, 10−25% 10CV, 25% 4CV) yielded product X
(51 mg, 40%,) a gum which was triturated with acetone (2 × 1 mL) to
aﬀord 22 (72 mg, 70%) as a pale-yellow solid. 1H NMR (400 MHz,
DMSO-d6) δ: 2.46 (app t, J = 6.2 Hz, 2H), 2.56−2.58 (m, 4H),
3.53−3.58 (m, 6H), 4.42 (bs, 1H), 6.04 (bs, 2H), 7.84 (s, 1H), 11.94
(bs, 1H). 13C NMR (100 MHz, DMSO-d6) δ: 47.6, 52.9, 58.5, 60.2,
83.3, 95.3, 117.6, 130.7, 155.1, 158.9, 160.0. HRMS (ESI) calculated
for C13H16ON7 [M − H]− 286.1422, found 286.1422. HPLC tR =
7.24 min (method C).
2-Amino-4-(3-hydroxypropylamino)-7H-pyrrolo[2,3-d]-
pyrimidine-5-carbonitrile (23). Prepared according to procedure B.
The remaining solid was triturated with cold H2O (2 × 2 mL), ﬁltered,
dried, and then triturated with Et2O (2 × 3 mL) to yield 23 (62 mg,
74%) as a pale-cream solid. 1H NMR (400 MHz, DMSO-d6) δ:
1.70−1.76 (m, 2H), 3.48−3.55 (m, 4H), 4.66 (t, J = 4.3 Hz, 1H), 5.95
(bs, 2H), 6.08 (t, J = 5.1 Hz, 1H), 7.68 (s, 1H), 11.82 (bs, 1H). 13C
NMR (100 MHz, DMSO-d6) δ: 32.6, 38.5, 59.6, 82.2, 94.7, 117.3,
129.1, 153.6, 156.8, 161.5. HRMS (ESI) calculated for C10H12NO [M
− H]− 231.1000, found 231.1001. HPLC tR = 3.66 min (method A).
(R)-2-Amino-4-(3-hydroxypyrrolidin-1-yl)-7H-pyrrolo[2,3-d]-
pyrimidine-5-carbonitrile (24). 5 (100 mg, 0.36 mmol), (3R)-3-
hydroxypyrrolidine (0.2 mL, 2.48 mmol), and TEA (0.15 mL,
1.13 mmol) in dioxane (2.5 mL) was heated in the microwave at
200 °C for 20 min. The reaction mixture was then diluted with EtOH
(8 mL) and KOH (2 pellets) added and heated at 90 °C for 24 h. The
reaction mixture was concentrated at reduced pressure, water (5 mL)
added, acidiﬁed to pH 5.7 (3 M HCl), and extracted with EtOAc
(10 mL × 3). The organic fractions were combined, dried over
anhydrous MgSO4, ﬁltered, and concentrated under reduced pressure
to give the crude product. The crude was triturated with Et2O to aﬀorded
24 (28 mg, 0.11 mmol, 33%). 1H NMR (500 MHz, DMSO-d6): d
1.85−1.94 (m, 1H), 1.94−2.04 (m, 1H), 3.56−3.64 (m, 1H),
3.70−3.85 (m, 3H), 4.39 (s, 1H), 4.99 (br s, 1H), 5.81 (s, 2H),
7.79 (s, 1H), 11.88 (br s, 1H). 13C NMR (125 MHz, DMSO-d6): d
33.0, 46.7, 57.3, 68.7, 83.4, 93.7, 118.6, 130.9, 154.7, 155.5, 159.8.
HRMS: calculated for C11H13ON6 245.1145 [M + H]
+, found
245.1143.
(R)-2-Amino-4-(3-hydroxypyrrolidin-1-yl)-7H-pyrrolo[2,3-d]-
pyrimidine-5-carbonitrile (25). Prepared according to procedure A.
Chromatographic puriﬁcation (Biotage SP4, 10 g cartridge, solvent
system: MeOH/EtOAc; gradient 0% 6CV, 0−10% 12CV, 10% 6CV)
yielded 25 (10 mg, 13%) as a light-brown solid; [α]D
20 −21.5o
(c = 0.37, DMSO). 1H NMR (400 MHz, DMSO-d6) δ: 1.85−1.92
(m, 1H), 1.94−2.03 (m, 1H), 3.58−3.61 (m, 1H), 3.70−3.83 (m, 3H),
4.36−4.41 (m, 1H), 5.01 (d, J = 3.4 Hz, 1H), 5.84 (bs, 2H), 7.80
(s, 1H), 11.84 (bs, 1H). 13C NMR (100 MHz, DMSO-d6) δ: 33.6,
47.3, 57.9, 69.3, 84.0, 94.3, 119.2, 131.5, 155.3, 156.0, 160.4. HRMS
(ESI) calculated forC11H11ON6 [M − H]− 243.1000, found 243.1001.
HPLC tR = 7.85 min (method C).
(R)-2-Amino-4-(2-(hydroximethyl)pyrrolidin-1-yl)-7H-pyrrolo[2,3-
d]pyrimidine-5-carbonitrile (26). Prepared according to procedure B.
The residue was suspended in MeOH, adsorbed on silica gel, and
concentrated in vacuo. Chromatographic puriﬁcation (Biotage SP4,
10 g cartridge, solvent system: MeOH/DCM; gradient 0% 4CV,
0−5% 4CV, 5% 4CV, 5−10% 4CV, 10% 4CV) yielded 26 (62 mg,
67%) as ﬂuﬀy oﬀ-white solid; [α]D
20 −96.3o (c = 0.55, DMSO). 1H
NMR (400 MHz, DMSO-d6) δ: 1.83−1.89 (m, 1H), 1.90−1.96
(m, 2H), 2.02−2.10 (m, 1H), 3.52−3.63 (m, 2H), 3.70−3.76 (m, 1H),
3.86−3.91 (m, 1H), 4.46−4.51 (m, 1H), 4.77 (t, J = 5.0 Hz, 1H), 5.81
(bs, 2H), 7.81 (d, J = 1.0 Hz, 1H), 11.89 (bs, 1H). 13C NMR
(100 MHz, DMSO-d6) δ: 24.6, 27.5, 51.1, 60.4, 62.3, 84.3, 94.5, 119.3,
131.6, 155.4, 156.2, 160.2. HRMS (ESI) calculated forC12H15ON6
[M + H]+ 259.1302, found 259.1299. HPLC tR = 7.26 min (method A).
(S)-2-Amino-4-(2-(hydroximethyl)pyrrolidin-1-yl)-7H-pyrrolo[2,3-
d]pyrimidine-5-carbonitrile (27). Prepared according to procedure B.
The residue was suspended in MeOH, adsorbed on silica gel, and
concentrated in vacuo. Chromatographic puriﬁcation (Biotage SP4,
10 g cartridge, solvent system: MeOH/DCM; gradient 0% 4CV,
0−5% 4CV, 5% 4CV, 5−10% 4CV, 10% 4CV) yielded 27 (68 mg,
73%) as ﬂuﬀy oﬀ-white solid; [α]D
20 −93.8o (c = 0.54, DMSO).
1H NMR (400 MHz, DMSO-d6) δ: 1.83−1.89 (m, 1H), 1.90−1.96
(m, 2H), 2.02−2.10 (m, 1H), 3.52−3.63 (m, 2H), 3.70−3.76 (m, 1H),
3.86−3.91 (m, 1H), 4.46−4.51 (m, 1H), 4.77 (t, J = 5.0 Hz, 1H), 5.81
(bs, 2H), 7.81 (d, J = 1.0 Hz, 1H), 11.89 (bs, 1H). 13C NMR
(100 MHz, DMSO-d6) δ: 24.6, 27.5, 51.1, 60.4, 62.3, 84.3, 94.5, 119.3,
131.6, 155.4, 156.2, 160.2. HRMS (ESI) calculated for C12H15ON6
[M + H]+ 259.1302, found 259.1298. HPLC tR = 7.26 min (method A).
2-Amino-4-((1R,4R)-4-hydroxycyclohexylamino)-7H-pyrrolo[2,3-
d]pyrimidine-5-carbonitrile (28). Prepared according to procedure B.
The remaining solid was suspended in MeOH, adsorbed on silica gel,
and concentrated in vacuo. Chromatographic puriﬁcation (Biotage
SP4, 10 g cartridge, solvent system: MeOH/EtOAc; gradient 0% 6CV,
0−15% 16CV, 15% 8CV) yielded a beige solid which was triturated
with MeOH (0.5 mL) to yield 28 (32 mg, 35%) as a white solid. 1H
NMR (400 MHz, DMSO-d6) δ: 1.26−1.34 (m, 2H), 1.41−1.52
(m, 2H), 1.83−1.88 (m, 2H), 1.92−1.98 (m, 2H), 3.41−3.49 (m, 1H),
3.97−4.08 (m, 1H), 6.67 (bs, 1H), 7.31 (bs, 2H), 7.85 (s, 1H), 12.68
(bs 1H). 13C NMR (100 MHz, DMSO-d6) δ: 30.2, 34.2, 49.5, 68.4,
84.3, 94.6, 116.2, 130.5, 147.1, 158.0, 160.4. HRMS (ESI) calculated
for C13H15ON6 [M + H]
+ 271.1313, found 271.1316. HPLC tR =
6.54 min (method A).
2-Amino-4-(cyclohexyl(2-hydroxyethyl)amino)-7H-pyrrolo[2,3-d]-
pyrimidine-5-carbonitrile (29). Prepared according to procedure B.
The remaining solid was suspended in MeOH, adsorbed on silica gel,
and concentrated in vacuo. Chromatographic puriﬁcation (Biotage
SP4, 10 g cartridge, solvent system: MeOH/DCM; gradient 0% 4CV,
0−5% 4CV, 5% 4CV, 5−10% 4CV, 10% 4CV) yielded 29 (51 mg,
40%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ: 1.05−1.14
(m, 1H), 1.36−1.45 (m, 2H), 1.53−1.61 (m, 3H), 1.71−1.77 (m, 4H),
3.44−3.48 (m, 2H), 3.54−3.49 (m, 1H), 4.16−4.21 (m, 1H), 4.55
(t, J = 5.4 Hz, 1H), 5.91 (bs, 2H), 7.84 (s, 1H), 11.95 (bs, 1H). 13C
NMR (100 MHz, DMSO-d6) δ: 25.4, 25.7, 31.1, 44.9, 58.9, 60.5, 84.2,
95.4, 118.2, 131.5, 155.8, 158.7, 160.1. HRMS (ESI) calculated
forC15H19ON6 [M − H]− 299.1626, found 299.1628. HPLC tR =
9.46 min (method A).
2-Amino-4-((1RS,2SR,3RS)-2,3-dihydroxycyclopentylamino)-7H-
pyrrolo[2,3-d]pyrimidine-5-carbonitrile (30). 5 (80 mg, 0.29 mmol),
37 (70 mg, 0.35 mmol), and Et3N (0.04 mL, 29 mg, 0.29 mmol) were
suspended in n-BuOH (4 mL) and reﬂuxed for 16 h. After cooling to
room temperature, EtOH (4 mL) and KOH (3 pellets) were added
and the reaction mixture was heated at 80 °C for 20 h. The mixture
was neutralized using 6 M HCl and subsequently concentrated in
vacuo. The remaining solid was suspended in MeOH, adsorbed on
silica gel, and concentrated in vacuo. Chromatographic puriﬁcation
(Biotage SP4, 50g cartridge, solvent system: MeOH/CHCl3; gradient
0% 4CV, 0−15% 14CV, 15% 4CV) yielded 30 (33 mg, 42%) as a
white solid. 1H NMR (400 MHz, DMSO-d6) δ: 1.29−1.38 (m, 1H),
1.47−1.55 (m, 1H), 1.87−1.96 (m, 1H), 2.18−2.27 (m, 1H),
3.72−3.75 (m, 1H), 3.89−3.93 (m, 1H), 4.28−4.36 (m, 1H), 4.39
(d, J = 3.3 Hz, 1H), 4.94 (d, J = 5.5 Hz, 1H), 5.66 (d, J = 7.1 Hz, 1H),
5.99 (bs, 2H), 7.69 (s, 1H), 11.83 (bs, 1H). 13C NMR (100 MHz,
DMSO-d6) δ: 27.0, 28.8, 55.4, 70.6, 77.8, 81.5, 94.2, 116.9, 128.4,
153.0, 156.5, 160.8. HRMS (ESI) calculated for C12H13O2N6
[M + H]+ 273.1105, found 273.1107. HPLC tR = 4.47 min (method A).
2-Amino-4-((1R,2S,3R,4S)-2,3,4-trihydroxycyclopentylamino)-7H-
pyrrolo[2,3-d]pyrimidine-5-carbonitrile (31). 5 (70 mg, 0.25 mmol),
42 (146 mg, 0.30 mmol), and Et3N (0.08 mL, 61 mg, 0.60 mmol)
were suspended in n-BuOH (4 mL) and reﬂuxed for 16 h. After
cooling to room temperature, EtOH (4 mL) and KOH (3 pellets)
were added and the reaction mixture was heated at 80 °C for 20 h. The
mixture was neutralized using 6 M HCl and subsequently concentrated
in vacuo. The remaining solid was suspended in MeOH, adsorbed on
silica gel, and concentrated in vacuo. Chromatographic puriﬁcation
(Biotage SP4, 10 g cartridge, solvent system: 5% NH4OH in MeOH/
CHCl3; gradient 2% 6CV, 2−15% 12CV, 10% 15CV) yielded a beige
solid which was further triturated with MeOH (0.2 mL) and Et2O
(2 mL) to yield 31 (24 mg, 33%) as a white solid; [α]D
20 −25.7°
(c = 0.12, DMSO). 1H NMR (400 MHz, DMSO-d6) δ: 1.23−1.29
(m, 1H), 2.5−2.551 (m, 1H), 3.67−3.68 (m, 1H), 3.80−3.81 (m, 1H),
3.91−3.93 (m, 1H), 4.30−4.36 (m, 1H), 4.58 (d, J = 3.6 Hz, 1H), 4.91
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(bs, 1H), 4.92 (bs, 1H), 5.70 (d, J = 7.5 Hz, 1H), 5.99 (bs, 2H), 7.69
(s, 1H), 11.83 (bs, 1H). 13C NMR (100 MHz, DMSO-d6) δ: 37.8,
55.2, 74.6, 76.8, 77.6, 94.1, 117.0, 128.5, 129.5, 153.1, 156.2, 160.9.
HRMS (ESI) calculated forC12H15O3N6 [M + H]
+ 291.1200, found
291.1189. HPLC tR = 6.40 min (method B).
3-(N,N-Dibenzylamino)cyclopent-1-ene (34). A mixture of cyclo-
pentene (12.3 mL, 9.18 g, 0.135 mol), NBS (6.01 g, 33.71 mmol), and
benzoyl peroxide (70%, 163 mg, 0.67 mmol) in CCl4 (21 mL) was
heated at reﬂux for 1 h. The reaction mixture was cooled to 0 °C,
ﬁltered through a pad of Celite (eluent CCl4), and solvent and
cyclopentene were distilled oﬀ in vacuo. The residue was dissolved in
CCl4 (30 mL), cooled to 0 °C, and N,N-dibenzylamine (16.2 mL,
16.60 g, 84.28 mmol) was added to the crude solution of bromide 33.
The mixture then warmed to room temperature and stirred for 30 min.
The reaction mixture was then ﬁltered, heated to 40 °C, and stirred at
this temperature for 1 h, then ﬁltered and stirred at room temperature
for 16 h. The mixture was then ﬁltered and concentrated in vacuo.
Chromatographic puriﬁcation (Biotage SP4, 100 g cartridge, solvent
system: 10% Et2O in Hex/Hex; gradient 0% 4CV, 0−10% 10CV)
yielded 34 (6.23 g, 70%) as a colorless oil. 1H NMR (400 MHz,
CDCl3) δ: 1.78−1.93 (m, 2H), 2.22−2.29 (m, 1H), 2.34−2.41 (m,
1H), 3.43 (d, J = 13.8 Hz, 2H), 3.64 (d, J = 13.8 Hz, 2H), 4.03−4.05
(m, 1H), 5.75−5.76 (m, 1H), 5.86−5.89 (m, 1H), 7.19−7.23 (m, 2H),
7.27−7.31 (m, 4H), 7.37−7.39 (m, 4H). 13C NMR (100 MHz,
CDCl3) δ: 23.4, 31.9, 54.5, 66.1, 126.8, 128.3, 128.8, 132.1, 133.3,
140.8.
(1RS,2SR,3RS)-3-(Dibenzylamino)cyclopentane-1,2-diol (35). A
solution of OsO4 in H2O (4% w/v, 0.32 mL, 13 mg, 0.05 mmol)
was added to a stirred solution of 51 (1.31 g, 4.98 mmol) and NMO
(1.33 g, 14.94 mmol) in acetone/H2O (4:1, 35 mL), and the resultant
mixture was stirred at room temperature for 4 h. Saturated aq Na2SO3
(5 mL) was then added, and the solution was stirred for an additional
30 min. Acetone was evaporated in vacuo, H2O (10 mL) was added,
and the aqueous layer was extracted with DCM (3 × 20 mL). The
organic layer was adsorbed on silica gel and concentrated in vacuo.
Chromatographic puriﬁcation (Biotage SP4, 50 g cartridge, solvent
system: EtOAc/Hex; gradient 10% 4CV, 10−20% 6CV, 20% 4CV,
20−60% 6CV; 60% 6CV) yielded 35 (1.06 g, 72%) as a white solid.
1H NMR (400 MHz, CDCl3) δ: 1.52−1.75 (m, 2H), 1.83−1.96 (m,
2H), 2.28 (bs, 1H), 2.37 (bs, 1H), 3.27 (app q, J = 8.4 Hz, 1H), 3.57
(d, J = 13.9 Hz, 2H), 3.78 (d, J = 13.9 Hz, 2H), 3.92 (app dd, J = 8.2,
5.2 Hz, 1H), 3.99−4.05 (m, 1H), 7.21−7.25 (m, 2H), 7.29−7.32
(m, 4H), 7.35−7.37 (m, 4H). 13C NMR (100 MHz, CDCl3) δ: 19.6,
29.0, 55.0, 65.1, 71.1, 74.6, 127.1, 128.4, 128.7, 139.9. HRMS (ESI)
calculated for C19H24O2N [M + H]
+ 298.1802, found 298.1798.
(1RS,2SR,3RS)-3-(Dibenzylamino)cyclopentane-1,2-diyl-diben-
zoate (36). Benzoyl chloride (1.62 mL, 1.96 g, 13.92 mmol) was
added dropwise to a stirred solution of 35 (1.03 g, 3.48 mmol) in dry
pyridine (30 mL) at 0 °C, left to warm to room temperature, and
stirred for 1 day. Pyridine was evaporated in vacuo, and the residue
was suspended in Et2O (40 mL), cooled to 0 °C, followed by addition
of saturated aqueous NaHCO3 (10 mL). The organic layer was then
washed with saturated aqueous NaHCO3 (3 × 20 mL) and sub-
sequently adsorbed on silica gel and concentrated in vacuo. Chroma-
tographic puriﬁcation (Biotage SP4, 50 g cartridge, solvent system:
10% Et2O in Hex/Hex; gradient 0% 3CV, 0−10% 3CV, 10% 4CV,
10−20% 4CV, 20% 4CV, 20−40% 6CV) yielded 36 (1.45 g, 84%) as a
white solid. 1H NMR (400 MHz, CDCl3) δ: 1.75−1.84 (m, 1H),
1.88−1.96 (m, 1H), 2.01−2.10 (m, 1H), 2.18−2.26 (m, 1H), 3.67
(d, J = 13.8 Hz, 2H), 3.77 (d, J = 13.8 Hz, 2H), 3.78−3.86 (m, 1H),
5.54 (dt, J = 5.0, 4.6 Hz, 1H), 5.67 (dd, J = 8.0, 5.0 Hz, 1H), 7.20−7.40
(m, 14 H), 7.49 (m, 1H), 7.55 (m, 1H), 7.76 (dd, J = 8.4, 1.3 Hz, 2H),
7.94 (dd, J = 8.4, 1.3 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ: 20.7,
27.6, 54.7, 62.2, 73.3, 74.0, 126.9, 128.3, 128.3, 128.4, 128.7, 129.6,
129.8, 130.1, 130.2, 132.9, 133.0, 139.7, 165.7, 165.9. HRMS (ESI)
calculated for C33H32O4N [M + H]
+ 506.2326, found 506.2321.
(1RS,2SR,3RS)-3-Aminocyclopentane-1,2-diyl dibenzoate (37).
Pd(OH)2/C (20% w/w, 700 mg) was added to a vigorously stirred
solution of 36 (1.42 g, 2.81 mmol) in EtOH/EtOAc (5:1, 60 mL), and
the resultant suspension was stirred at room temperature under H2
(1 atm) for 16 h. The suspension was ﬁltered through a Celite pad
(eluent MeOH) and concentrated in vacuo. The residue was triturated
with Et2O (2 × 20 mL) to give 37 (908 mg, 98%) as a white solid.
1H
NMR (400 MHz, DMSO-d6) δ: 1.73−1.82 (m, 1H), 1.93−2.02
(m, 1H), 2.32−2.43 (m, 2H), 3.93 (app dt, J = 8.0, 7.6 Hz, 1H), 5.49
(dd, J = 7.5, 5.1 Hz, 1H), 5.59−5.63 (m, 1H), 7.42−7.49 (m, 4H),
7.61−7.66 (m, 2H), 7.86−7.89 (m, 2H), 8.38 (bs, 2H). 13C NMR
(100 MHz, DMSO-d6) δ: 25.2, 27.7, 53.4, 73.2, 76.6, 129.1, 129.2,
129.6, 129.7, 129.8, 129.9, 134.1, 134.1, 165.4, 165.5. HRMS (ESI)
calculated for C19H20O4N [M + H]
+ 326.1387, found 326.1382.
Di-tert-butyl-[(1R,4S)-4-hydroxycyclopent-2-en-1-yl]imidodicar-
bonate (39). A suspension of sodium di-tert-butyl-iminodicarboxylate,
previously prepared by reaction of di-tert-butyl-iminodicarboxy-
late (1.195 g, 5.50 mmol) with NaH (60% suspension in mineral
oil) (132 mg, 5.50 mmol) in dry THF (18 mL), was cannulated to a
room temperature solution of (1R,4S)-4-hydroxycyclopent-2-enyl
acetate (521 mg, 3.67 mmol), PPh3 (144 mg, 0.55 mmol), and
Pd(PPh3)4 (636 mg, 0.55 mmol) in dry THF/DMF (1:1) (16 mL).
The reaction mixture was heated at 50 °C for 1 day, then diluted with
MeOH (10 mL) and dry loaded on to silica. Chromatographic
puriﬁcation (Biotage SP4, 50 g cartridge, solvent system: EtOAc/Hex;
gradient 0% 4CV, 0−20% 10CV, 20% 6CV) yielded 39 (463 mg, 42%)
as a colorless oil that solidiﬁes upon standing to aﬀord a white solid.
1H NMR (400 MHz, CDCl3) δ: 1.48 (s, 18H), 1.83 (dt, J = 15.1,
2.3 Hz, 1H), 2.68 (ddd, J = 15.1, 9.3, 7.9 Hz, 1H), 3.20 (bs, 1H),
4.57−4.61 (m, 1H), 5.09 (app dq, J = 9.3, 2.3 Hz, 1H), 5.74 (dd, J =
5.4, 2.3 Hz, 1H), 6.04 (dt, J = 5.4, 2.3 Hz, 1H). 13C NMR (100 MHz,
CDCl3) δ: 28.1, 38.9, 60.3, 75.8, 82.9, 131.5, 136.9, 153.4.
Di-tert-butyl-[(1R,2S,3R,4S)-2,3,4-trihydroxycyclopentyl] imidodi-
carbonate (40). A solution of OsO4 in H2O (4% w/v, 0.06 mL, 3 mg,
0.01 mmol) was added to a solution of 39 (120 mg, 0.40 mmol) and
NMO (141 mg, 1.20 mmol) in a 4:1 mixture acetone/H2O (10 mL).
The solution was stirred at room temperature for 1 day. Saturated
aqueous Na2SO3 (5 mL) was added, and the reaction mixture was
stirred for 30 min. Acetone was removed in vacuo, and the aqueous
layer was extracted with EtOAc (4 × 20 mL). The organic layer was
adsorbed on silica gel and concentrated in vacuo. Chromatographic
puriﬁcation (Biotage SP4, 10 g cartridge, solvent system: EtOAc/
DCM; gradient 20% 6CV, 20−80% 8CV, 80% 8CV) yielded 40
(71 mg, 53%) as a colorless oil that solidiﬁes upon standing to aﬀord a
white solid. 1H NMR (400 MHz, CDCl3) δ: 1.49 (s, 18H), 1.79−1.85
(m, 1H), 2.53−2.62 (m, 1H), 2.91 (bs, 3H), 3.98−3.99 (m, 1H),
4.01−4.04 (m, 1H), 4.39−4.45 (m, 1H), 4.55−4.58 (m, 1H). 13C
NMR (100 MHz, CDCl3) δ: 28.0, 34.1, 61.9, 74.9, 75.1, 77.3, 83.6,
153.7. HRMS (ESI) calculated for C15H27O7NNa [M + Na]
+
356.1680, found 356.1682.
(1S,2R,3S,4R)-4-(Bis(tert-butoxycarbonyl)amino)cyclopentane-
1,2,3-triyl tribenzoate (41). Benzoyl chloride (0.33 mL, 397 mg,
2.83 mmol) was added dropwise to a stirred solution of 40 (235 mg,
0.71 mmol) in dry pyridine (6 mL) at 0 °C and left to warn to room
temperature and stirred for 1 day. Pyridine was evaporated in vacuo,
and the residue was partitioned between Et2O (40 mL) and saturated
aqueous NaHCO3 (10 mL). The organic layer was separated and
washed with saturated aqueous NaHCO3 (3 × 20 mL) and sub-
sequently adsorbed on silica gel and concentrated in vacuo. Chroma-
tographic puriﬁcation (Biotage SP4, 50 g cartridge, solvent system:
Et2O/Hex; gradient 0% 6CV, 0−20% 10CV, 20% 6CV) yielded 41
(338 mg, 74%) as a colorless oil that solidiﬁed upon standing to
aﬀord a white solid. 1H NMR (400 MHz, CDCl3) δ: 1.51 (s, 18H),
2.21−2.29 (m, 1H), 2.75−2.82 (m, 1H), 5.00−5.07 (m, 1H),
5.58−5.64 (m, 1H), 5.98−6.05 (m, 2H), 7.29−7.34 (m, 4H),
7.41−7.51 (m, 3H), 7.54−7.63 (m, 2H), 7.90−7.93 (m, 4H),
8.08−8.13 (m, 2H). 13C NMR (100 MHz, CDCl3) δ: 28.1, 30.3,
58.3, 73.7, 74.3, 75.6, 83.3, 128.3, 128.4, 128.5, 129.4, 129.4, 129.6,
129.7, 129.8, 129.9, 133.1, 133.1, 133.2, 152.5, 165.3, 165.4, 166.0.
HRMS (ESI) calculated for C36H39O10NNa [M + Na]
+ 668.2463,
found 668.2463.
(1S,2R,3S,4R)-4-Aminocyclopentane-1,2,3-triyl-tribenzoate Hy-
drochloride (42). 41 (297 mg, 0.46 mmol) was placed in an oven-dry
round-bottom ﬂask, purged with N2, cooled to 0 °C, and subsequently
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treated with 4 M HCl in 1,4-dioxane (10 mL). The mixture was
left to warm to room temperature, stirred for 16 h, and con-
centrated in vacuo. The residue was triturated with Et2O (5 × 1 mL)
to yield 42 (168 mg, 76%) as a white solid. 1H NMR (400 MHz,
CDCl3) δ: 2.01−2.09 (m, 1H), 2.97−3.04 (m, 1H), 4.07−4.14
(m, 1H), 5.51−5.56 (m, 1H), 5.73−5.76 (m, 1H), 5.82−5.83 (m, 1H),
7.43−7.49 (m, 4H), 7.55−7.59 (m, 2H), 7.63−7.73 (m, 3H),
7.87−7.92 (m, 4H), 8.03−8.05 (m, 2H), 8.66 (bs, 3H). 13C NMR
(100 MHz, CDCl3) δ: 31.6, 51.6, 73.6, 74.6, 74.8, 129.0, 129.1, 129.2,
129.2, 129.3, 129.4, 129.8, 129.9, 129.9, 134.2, 164.9, 165.2, 165.4.
HRMS (ESI) calculated forC26H24O6N [M + H]
+ 446.1598, found
446.1599.
2-Amino-4-phenyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
(43). 5 (96 mg 0.35 mmol), phenyl boronic acid (73 mg, 0.60 mmol),
and Pd(PPh3)4 (0.041 g, 0.047 mmol) were suspended in a mixture of
IPA/H2O (3:1.5 mL) and degassed. t-Butylamine (0.19 mL,
1.81 mmol) was added, and the mixture was irradiated at 160 °C
for 40 min. The resulting solution was diluted with EtOH (8 mL) and
KOH (2 pellets) were added and the mixture was heated to 90 °C for
20 h. The reaction mixture was then concentrated under reduced
pressure, and the resulting mixture was suspended in water, pH
adjusted to pH 5.3, extracted into EtOAc (2 × 100 mL), and dried
over MgSO4. The resulting solid was puriﬁed by column chromatog-
raphy (100% hexane−100% ethyl acetate) and triturated with diethyl
ether to aﬀord the title compound 43 as a light-brown solid (4.9 mg,
0.0208 mmol, 6.0%). 1H NMR (400 Hz, DMSO-d6): δ 6.63 (br s,
2H), 7.54−7.55 (m, 3H), 7.78−7.80 (m, 2H), 8.12 (s, 1H), 12.40
(br s, 1H). HRMS (ESI) calculated for C13H9N5 [M + H]
+ 236.0931,
found 236.0930.
2-Amino-4-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimdine-5-car-
bonitrile (44). 5 (115 mg, 0.42 mmol), 4-hydroxyphenyl boronic acid
(92 mg, 0.67 mmol), and Pd(PPh3)4 (49 mg, 0.042 mmol) were
suspended in a mixture of IPA/H2O (3:1.5 mL) and degassed.
t-Butylamine (0.18 mL, 1.71 mmol) was added, and the mixture was
irradiated at 160 °C for 40 min. The reaction mixture was then
concentrated under reduced pressure, and the resulting solid was
triturated with methanol, ﬁltered, and dried. EtOH (9 mL) was added
KOH (2 pellets) and the mixture heated to 90 °C for 48 h. The
reaction mixture was concentrated under reduced pressure, water was
added, and the mixture was pH adjusted to pH 6 and extracted into
EtOAc. The organic layer was dried over MgSO4 and concentrated
under reduced pressure to aﬀord the title compound 44 as a brown
solid 10.1 mg, 0.040 mmol, 67%). 1H NMR (400 Hz, DMSO-d6): δ
6.51 (br s, 2H), 6.89 (d, 2H, J = 8.4 Hz), 7.67 (d, 2H, J = 8.8 Hz), 8.08
(s, 1H), 9.90 (s, 1H), 12.28 (br s, 1H). HRMS (ESI) calculated for
C13H9N5O 252.0880 [M + H]
+, found 252.0880. HPLC: tR = 8.62 min
(70.46%).
2-Amino-4-(4-ﬂuorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-car-
bonitrile 945). 5 (100 mg 0.31 mmol), Pd-118 (20 mg, 0.03 mmol),
t-butylamine (160 μL, 1.55 mmol), and 4-ﬂuorophenylboronic acid
(69 mg, 0.5 mmol) were suspended in a 2:1 mixture i-PrOH/H2O
(4.5 mL) and were irradiated with microwaves at 160 °C for 40 min.
Once cooled to room temperature, the reaction mixture was con-
centrated under reduced pressure. To this was added EtOH (5 mL)
and KOH (2 pellets), and the reaction mixture was reﬂuxed at 90 °C
for 20 h. The mixture was then concentrated under reduced pressure,
and the crude material was then suspended in H2O and adjusted to
pH 5 with 1 M HCl. The solution was then extracted with EtOAc
(2 × 50 mL); the organic layer was adsorbed on silica gel and con-
centrated under reduced pressure. Chromatographic puriﬁcation
(EtOAc/Hex: 50% 4CV, 50−75% 6CV, 75% 4CV, 75−100% 7CV,
100% 6CV) yielded a beige solid that was triturated with Et2O to
aﬀord the title compound 45 as a beige solid (13 mg, 0.05 mmol,
17%). 1H NMR (400 MHz, DMSO-d6): δ 6.62 (s, 2H), 7.36 (t, J =
8.3 Hz, 2H), 7.83 (t, J = 7.7 Hz, 2H), 8.12 (s, 1H), 12.36 (s, 1H).
HRMS: calculated for C13H9N5F [M + H]
+ 254.0837, found 254.0831.
4-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimdin-4-yl)benzamide
(46). 5 (101 mg, 0.36 mmol), 4-aminocarbonyl phenylboronic acid
(96 mg, 0.58 mmol), and Pd(PPh3)4 (40 mg, 0.035 mmol) were
suspended in a mixture of IPA/H2O (3:1.5 mL) and degassed.
t-Butylamine (0.20 mL, 1.90 mmol) was added, and the mixture was
irradiated at 160 °C for 40 min. The resulting solution was diluted
with EtOH (6 mL) and KOH (2 pellets) were added and the mixture
was heated to 90 °C for 30 h. The reaction mixture was then con-
centrated under reduced pressure, and the resulting mixture was
suspended in water, pH adjusted to pH 5.2, extracted into EtOAc
(2 × 100 mL), and dried over MgSO4. The mixture was then con-
centrated under reduced pressure, triturated with diethyl ether and
methanol, and ﬁltered. The solid and ﬁltrate were combined and
puriﬁed by column chromatography (100% hexane−100% ethyl
acetate). The isolated compound was triturated with diethyl ether,
ﬁltered under reduced pressure, and dried to aﬀord the title compound
46 as an oﬀ-white solid (6 mg, 0.022 mmol, 5.9%). 1H NMR (400 Hz,
DMSO-d6): δ 6.68 (s, 2H), 7.51 (br s, 1H), 7.85 (d, 2H, J = 9.2 Hz),
8.40 (d, 2H, J = 10.4 Hz), 8.14 (br s, 1H), 8.16 (s, 1H), 12.40 (br s,
1H). HRMS (ESI) calculated for C14H8N6O [M + H]
+ 277.0843,
found 277.0844. HPLC: tR = 7.94 min (method A) (76.01%).
2-Amino-4-(4-hydroxymethyl)phenyl-7H-pyrrolo[2,3-d]-
pyrimidine-5-carbonitrile (47). 5 (103 mg, 0.37 mmol), 4-hydro-
xymethyl)phenyl boronic acid (99 mg, 0.65 mmol), and Pd-118
(47 mg, 0.072 mmol) were suspended in a mixture of IPA/H2O
(3:1.5 mL) and degassed. t-Butylamine (0.20 mL, 1.90 mmol) was
added, and the mixture was irradiated at 160 °C for 40 min. The
resulting solution was diluted with EtOH (8 mL) and KOH (2 pellets)
were added and the mixture was heated to 90 °C for 20 h. The
reaction mixture was then concentrated under reduced pressure,
and the resulting mixture was suspended in water, pH adjusted to
pH 5.3, extracted into EtOAc (2 × 100 mL), and dried over MgSO4.
The resulting solid was puriﬁed by column chromatography (100%
hexane−100% ethyl acetate) to aﬀord the title compound 47 as an
oﬀ-white solid (28.5 mg, 0.108 mmol, 29%). 1H NMR (400 Hz,
DMSO-d6): δ 4.61 (d, 2H, J = 5.6 Hz), 5.34 (t, 1H, J = 5.8 Hz),
6.60 (br s, 2H), 7.47 (d, 2H, J = 7.6 Hz), 7.77 (d, 2H, J = 8.0 Hz), 8.11
(s, 1H), 12.34 (br s, 1H). HRMS (ESI) calculated for C14H11N5O
[M + H]+ 264.0891, found 264.0891. HPLC: tR = 8.45 min (method A)
(94.35%).
4-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl) -
benzenesulfonamide (48). 5 (100.6 mg, 0.36 mmol), 4-sulpham-
oylbenzene boronic acid (124 mg 0.62 mmol), Pd-118 (43 mg
0.066 mmol) were suspended in a mixture of IPA/H2O (3:1.5 mL)
and degassed. t-Butylamine (0.195 mL, 1.86 mmol) was added and the
mixture was irradiated at 160 °C for 40 min. The resulting solution
was diluted with EtOH (6 mL) and KOH (2 pellets) were added and
the mixture was heated to 90 °C for 20 h. The reaction mixture was
then concentrated under reduced pressure and the resulting mixture
was suspended in water, pH adjusted to pH 5.5, extracted into EtOAc
(2 × 100 mL) and dried over MgSO4. The resulting solid was puriﬁed
by column chromatography (100% hexane−100% ethyl acetate) and
triturated with diethyl ether to aﬀord the title compound 48 as an
oﬀ-white solid (19.1 mg, 0.0608 mmol, 17%). 1H NMR (400 Hz,
DMSO-d6): δ 6.70 (br s, 2H), 7.54 (br s, 2H), 7.97 (br s, 4H), 8.17
(s, 1H), 12.45 (br s, 1H). HRMS (ESI) calculated for C13H8N6O2S
[M + H]+ 313.0513, found 313.0517. HPLC: tR = 8.33 min (method A)
(94.29%).
2-Amino-4-(4-(methylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]-
pyrimidine-5-carbonitrile (49). 5 (104 mg, 0.38 mmol), (4-meth-
ylsulfonyl)benzene boronic acid (128 mg, 0.64 mmol), and Pd-118
(25 mg, 0.038 mmol) were suspended in a mixture of IPA/H2O
(3:1.5 mL) and degassed. t-Butylamine (0.22 mL, 2.09 mmol) was
added, and the mixture was irradiated at 160 °C for 40 min. The
resulting solution was diluted with EtOH (8 mL) and KOH (2 pellets)
were added and the mixture was heated to 90 °C for 22 h. The
reaction mixture was then concentrated under reduced pressure, and
the resulting mixture was suspended in water, pH adjusted to pH 5.7,
extracted into EtOAc (2 × 100 mL), and dried over MgSO4. The
resulting solid was puriﬁed by column chromatography (100%
hexane−100% ethyl acetate), triturated with diethyl ether, ﬁltered,
and dried to aﬀord the title compound 49 as a pale-yellow solid
(54.8 mg, 0.175 mmol, 47%). 1H NMR (500 Hz, DMSO-d6): δ 3.30
(br s, 3H), 6.67 (br s, 2H), 8.03 (d, 2H, J = 8.5 Hz), 8.09 (d, 2H,
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J = 8.5 Hz), 8.17 (s, 1H), 12.45 (br s, 1H). HRMS (ESI) calculated
for C14H10N5O2S [M + H]
+ 312.0561, found 312.0564. HPLC: tR =
8.97 min (method A).
N-(4-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)-
methanesulfonamide (50). 5 (0.103 g, 0.37 mmol), 4-(meth-
ylsulfonyl)aminobenzene boronic acid (0.121 g, 0.56 mmol), Pd-118
(0.027 g, 0.041 mmol) were suspended in a mixture of IPA/H2O
(3:1.5 mL) and degassed. t-Butylamine (0.20 mL, 1.90 mmol) was
added, and the mixture was irradiated at 160 °C for 40 min. The
resulting solution was diluted with EtOH (8 mL) and KOH (2 pellets)
were added and the mixture was heated to 90 °C for 22 h. The reac-
tion mixture was then concentrated under reduced pressure, and the
resulting mixture was suspended in water, pH adjusted to pH 5.7,
extracted into EtOAc (2 × 100 mL), and dried over MgSO4. The
resulting solid was puriﬁed by column chromatography (100%
hexane−100% ethyl acetate), triturated with diethyl ether, ﬁltered,
and dried to aﬀord the title compound 50 as a pale-yellow solid
(0.0399 g, 0.122 mmol, 32.7%). 1H NMR (400 Hz, DMSO-d6): δ 3.08
(s, 3H), 6.55 (br s, 2H), 7.34 (d, 2H, J = 8.8 Hz), 7.78 (d, 2H, J =
8.4 Hz), 8.10 (s, 1H), 10.08 (br s, 1H), 12.33 (br s, 1H). HRMS (ESI)
calculated for C14H11N6O2S [M + H]
+ 327.0670, found 327.0673.
HPLC: tR = 8.92 min (method A) (85.80%).
4-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-(p-tolyl)-
benzenesulfonamide (51). 5 (100 mg, 0.36 mmol), 4-(N-p-toly-
lsulfamoyl)phenylboronic acid (168 mg, 0.58 mmol), and Pd-118
(23 mg, 0.03 mmol) in IPA/H2O (3:1.5 mL) was degassed with nitro-
gen. t-Butylamine (0.19 mL, 1.8 mmol) was added, and the mixture
was heated in the microwave at 160 °C for 40 min. The reaction
mixture was then diluted with EtOH (4 mL), KOH (2 pellets) added
and heated at 90 °C for 24 h. The reaction mixture was concentrated
under reduced pressure, and the resulting mixture was suspended in
water (5 mL), acidiﬁed to pH 5.7 (3 M HCl) and extracted with
EtOAc (10 mL × 3). The organic fractions were combined, dried over
anhydrous MgSO4, ﬁltered and concentrated under reduced pressure
to give the crude product. Puriﬁcation by ﬂash column chromatog-
raphy (silica gel with EtOAc (75−100%) in hexane aﬀorded the title
compound 51 as an oﬀ-white solid (0.005 g, 0.01 mmol, 3%).
1H NMR (400 Hz, DMSO-d6): 2.18 (s, 3H), 6.69 (br s, 2H), 6.98
(d, 2H, J = 8.4 Hz), 7.03 (d, 2H, J = 8.4 Hz), 7.84 (d, 2H, J = 8.4 Hz),
7.88 (d, 2H, J = 8.4 Hz), 8.14 (s, 1H), 10.20 (s, 1H), 12.43 (br s, 1H).
HRMS: calculated for C20H15O2N6S [M + H]
+ 403.0983, found
403.0986.
4-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methyl-
benzenesulfonamide (52). 5 (115 mg, 0.42 mmol), 4-((meth-
ylamino)sulphonyl)benzene boronic acid (134 mg 0.62 mmol), and
Pd-118 (32 mg, 0.049 mmol) were suspended in a mixture of IPA/
H2O (3:1.5 mL) and degassed. t-Butylamine (0.22 mL, 2.09 mmol)
was added, and the mixture was irradiated at 160 °C for 40 min. The
resulting solution was diluted with EtOH (8 mL) and KOH (2 pellets)
were added and the mixture was heated to 90 °C for 22 h. The
reaction mixture was then concentrated under reduced pressure, and
the resulting mixture was suspended in water, pH adjusted to pH 5.5,
extracted into EtOAc (2 × 100 mL), and dried over MgSO4. The
resulting solid was puriﬁed by column chromatography (100%
hexane−100% ethyl acetate), triturated with diethyl ether, ﬁltered,
and dried to aﬀord the title compound 52 as a pale-yellow solid
(47.2 mg, 0.144 mmol, 35%). 1H NMR (400 Hz, DMSO-d6): δ 2.46
(d, 3H, J = 4.8 Hz), 6.71 (br s, 2H), 7.60 (q, 1H, J = 4.9 Hz), 7.92
(d, 2H, J = 8.0 Hz), 7.98 (d, 2H, J = 8.4 Hz), 8.16 (s, 1H), 12.45 (br s,
1H). HRMS (ESI) calculated for C14H11N6O2S [M + H]
+ 327.0670,
found 327.0674. HPLC: tR = 9.24 min (method A) (82.18%).
2-Amino-4-(3-hydroyphenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-car-
bonitrile (53). 5 (113 mg, 0.41 mmol), 3-hydroxyphenyl boronic acid
(95 mg, 0.69 mmol), and Pd-118 (33 mg 0.051 mmol) were sus-
pended in a mixture of IPA/H2O (3:1.5 mL) and degassed.
t-Butylamine (0.22 mL, 2.09 mmol) was added, and the mixture was
irradiated at 160 °C for 40 min. The resulting solution was diluted
with EtOH (8 mL) and KOH (2 pellets) were added and the mixture
was heated to 90 °C for 22 h. The reaction mixture was then
concentrated under reduced pressure, and the resulting mixture was
suspended in water, pH adjusted to pH 5.5, extracted into EtOAc
(2 × 100 mL), and dried over MgSO4. The resulting solid was puriﬁed
by column chromatography (100% hexane−100% ethyl acetate)
to aﬀord the title compound 53 as an oﬀ-white solid (12 mg,
0.048 mmol, 11.7%). 1H NMR (400 Hz, DMSO-d6): δ 6.58 (br s, 2H),
6.91 (d, 1H, J = 8.0 Hz), 7.15−7.19 (m, 2H), 7.31 (t, 1H, J = 7.6 Hz),
8.09 (s, 1H), 9.62 (s, 1H), 12.33 (br s, 1H). HRMS (ESI) calculated
for C13H7N5O [M + H]
+ 250.0734, found 250.0737. HPLC: tR =
8.75 min (method A).
2-Amino-4-(3-ﬂuorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-car-
bonitrile (54). 5 (104 mg, 0.38 mmol), 3-ﬂuorobenzene boronic acid
(85 mg, 0.61 mmol), and Pd(PPh3)4 (45 mg, 0.039 mmol) were
suspended in a mixture of IPA/H2O (3:1.5 mL) and degassed.
t-Butylamine (0.16 mL, 1.52 mmol) was added, and the mixture was
irradiated at 160 °C for 40 min. The reaction mixture was then
concentrated under reduced pressure, and the resulting solid was
triturated with methanol, ﬁltered, and dried to give the intermediate
compound as an oﬀ-white solid (28.3 mg, 0.084 mmol, 22%).
To EtOH (10 mL) was added KOH (2 pellets) and the mixture
heated to 90 °C for 20 h. The reaction mixture was then concentrated
under reduced pressure and suspended in water. The mixture was
then pH adjusted to pH 5.8 and extracted into EtOAc (2 × 100 mL),
dried over MgSO4, and concentrated under reduced pressure. The
resulting solid was triturated with diethyl ether, ﬁltered, and dried
to aﬀord the title compound 54 as an oﬀ-white solid (12.2 mg,
0.048 mmol, 58%). 1H NMR (400 Hz, DMSO-d6): δ 6.67 (br s, 2H), 7.39
(t, 1H, J = 7.5 Hz), 7.55−7.63 (m, 3H), 8.15 (s, 1H), 12.40 (br s, 1H).
HRMS (ESI) calculated for C13H8N5F [M + H]
+ 254.0837, found
254.0833. HPLC: tR = 10.42 min (method A) (90.05%).
3-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimdin-4-yl)benzamide
(55). 5 (112 mg, 0.40 mmol), 3-(aminocarbonyl)phenyl boronic acid
(108 mg, 0.65 mmol), and Pd-118 (37 mg, 0.056 mmol) were
suspended in a mixture of IPA/H2O (3:1.5 mL) and degassed.
t-Butylamine (0.21 mL, 2.0 mmol) was added, and the mixture was
irradiated at 160 °C for 40 min. The resulting solution was diluted
with EtOH (8 mL) and KOH (2 pellets) were added and the mixture
was heated to 90 °C for 24 h. The reaction mixture was then
concentrated under reduced pressure, and the resulting mixture was
suspended in water, pH adjusted to pH 5.5, extracted into EtOAc
(2 × 100 mL), and dried over MgSO4. The resulting solid was puriﬁed
by column chromatography (100% hexane−100% ethyl acetate−5%
methanol/ethyl acetate) to aﬀord the title compound 55 as a yellow
solid (34.2 mg, 0.123 mmol, 30%).1H NMR (400 Hz, DMSO-d6): δ
6.67 (br s, 2H), 7.45 (br s, 1H), 7.61 (t, 1H, J = 7.6 Hz), 7.91 (d, 1H,
J = 7.6 Hz), 8.01−8.05 (m, 2H), 8.14 (s, 1H), 8.30 (br s, 1H), 12.45
(br s, 1H). HRMS (ESI) calculated for C14H9N5O [M + H]
+ 277.0843,
found 277.0846. HPLC: tR = 8.17 min (method A) (46.30%).
2-Amino-4-(3-(hydroxymethyl)phenyl)-7H-pyrrolo[2,3-d]-
pyrimidine-5-carbonitrile (56). 5 (103 mg, 0.37 mmol), 3-(hydro-
xymethyl)phenyl boronic acid (94 mg, 0.62 mmol), and Pd-118
(53 mg, 0.081 mmol) were suspended in a mixture of IPA/H2O (3:1.5
mL) and degassed. t-Butylamine (0.20 mL, 1.90 mmol) was added,
and the mixture was irradiated at 160 °C for 40 min. The resulting
solution was diluted with EtOH (8 mL) and KOH (2 pellets) were
added and the mixture was heated to 90 °C for 20 h. The reaction
mixture was then concentrated under reduced pressure, and the
resulting mixture was suspended in water, pH adjusted to pH 5.5,
extracted into EtOAc (2 × 100 mL), and dried over MgSO4. The
resulting solid was puriﬁed by column chromatography (100%
hexane−100% ethyl acetate), triturated with diethyl ether, ﬁltered,
and dried to aﬀord the title compound 56 as a yellow solid (30.5 mg g,
0.115 mmol, 31%). 1H NMR (400 Hz, DMSO-d6): δ 4.60 (d, 2H, J =
4.4 Hz), 5.28 (t, 1H, J = 5.2 Hz), 6.60 (br s, 2H), 7.49 (br s, 2H),
7.65−7.66 (m, 1H), 7.74 (s, 1H), 8.11 (s, 1H), 12.20 (br s, 1H).
HRMS (ESI) calculated for C14H9N5O [M + H]
+ 264.0891, found
264.0894. HPLC: tR = 8.62 min (method A).
3-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl) -
benzenesulfonamide (57). 5 (102 mg g, 0.37 mmol), 3-(amino-
sulphonyl)benzene boronic acid (122 mg, 0.61 mmol), and Pd-118
(24 mg, 0.037 mmol) were suspended in a mixture of IPA/H2O
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(3:1.5 mL) and degassed. t-Butylamine (0.20 mL, 1.90 mmol) was
added, and the mixture was irradiated at 160 °C for 40 min. The
resulting solution was diluted with EtOH (8 mL) and KOH (2 pellets)
were added, and the mixture was heated to 90 °C for 24 h. The
reaction mixture was then concentrated under reduced pressure, and
the resulting mixture was suspended in water, pH adjusted to pH 5.7,
extracted into EtOAc (2 × 100 mL), and dried over MgSO4. The
resulting solid was puriﬁed by column chromatography (100%
hexane−100% ethyl acetate) to aﬀord the title compound 57 as a
pale solid (43.2 mg, 0.138 mmol, 38%). 1H NMR (400 Hz, DMSO-d6):
δ 6.74 (br s, 2H), 7.44 (br s, 2H), 7.74 (t, 1H, J = 7.8 Hz), 8.00 (t, 2H,
J = 7.2 Hz), 8.17 (s, 1H), 8.23 (br s, 1H), 12.45 (br s, 1H). HRMS
(ESI) calculated for C13H9N6S [M + H]
+ 313.0513, found 313.0516.
HPLC: tR = 8.44 min (method A) (93.47%).
2-Amino-4-(2-hydroxyphenyl)-77H-pyrrolo[2,3-d]pyrimidine-5-
carbonitrile (58). 5 (117 mg, 0.36 mmol), 2-hydroxybenzene boronic
acid (94 mg, 0.68 mmol), and Pd-118 (26 mg, 0.040 mmol) were
suspended in a mixture of IPA/H2O (3:1.5 mL) and degassed.
t-Butylamine (0.20 mL, 1.90 mmol) was added, and the mixture was
irradiated at 160 °C for 40 min. The resulting solution was diluted
with EtOH (8 mL) and KOH (2 pellets) were added and the mixture
was heated to 90 °C for 24 h. The reaction mixture was then concen-
trated under reduced pressure, and the resulting mixture was
suspended in water, pH adjusted to pH 5.3, extracted into EtOAc
(2 × 100 mL), and dried over MgSO4. The mixture was then
concentrated under reduced pressure, triturated with diethyl ether,
and puriﬁed by column chromatography (100% hexane−100% ethyl
acetate). The resulting solid was triturated with diethyl ether, ﬁltered
under reduced pressure, and dried to aﬀord the title compound 58 as a
bright-yellow solid (30.7 mg, 0.122 mmol, 34%). 1H NMR (400 Hz,
DMSO-d6): δ 6.99 (t, 1H, J = 7.5 Hz), 7.07 (d, 1H, J = 8.0 Hz), 7.46
(d of t, 1H, J = 1.5, 7.0 Hz), 7.56 (d of d, 1H, J = 2.0, 1.5 Hz), 8.36
(s, 1H). HRMS (ESI) calculated for C15H10N2O2 [M + H]
+ 250.0737,
found 250.0735. HPLC: tR = 10.11 min (method A).
2-Amino-4-(2-ﬂuorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-car-
bonitrile (59). 5 (100 mg, 0.31 mmol), Pd-118 (20 mg, 0.03 mmol),
t-butylamine (160 μL, 1.55 mmol), and 2-ﬂuorophenylboronic acid
(69 mg, 0.5 mmol) were suspended in a 2:1 mixture i-PrOH/H2O
(4.5 mL) and were irradiated with microwaves at 160 °C for 40 min.
Once cooled to room temperature, the reaction mixture was
concentrated under reduced pressure. To this was added EtOH
(5 mL) and KOH (2 pellets) and the reaction mixture was reﬂuxed t at
90 °C for 20 h. The mixture was then concentrated under reduced
pressure, and the crude material was then suspended in H2O and
adjusted to pH 5 with 1 M HCl. The solution was then extracted with
EtOAc (2 × 50 mL); the organic layer was adsorbed on silica gel and
concentrated under reduced pressure. Chromatographic puriﬁcation
(EtOAc/Hex: 50% 4CV, 50−75% 6CV, 75% 4CV, 75−100% 7CV,
100% 6CV) yielded a beige solid that was triturated with Et2O to
aﬀord the title compound 59 and as a beige solid (16 mg g, 0.06 mmol,
20%). 1H NMR (400 MHz, DMSO-d6): δ 6.68 (s, 2H), 7.35 (t, J =
8.3 Hz, 2H), 7.58 (t, J = 7.7 Hz, 2H), 8.06 (s, 1H), 12.34 (s, 1H).
HRMS (ESI) calculated for C13H9N5F [M + H]
+ 254.0837 found
254.0831.
2-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide
(60). 5 (104 mg, 0.32 mmol), 2-(aminocarbonyl)benzne boronic acid
(87 mg, 0.53 mmol), and Pd-118 (21 mg, 0.032 mmol) were
suspended in a mixture of IPA/H2O (3:1.5 mL) and degassed.
t-Butylamine (0.18 mL, 1.71 mmol) was added, and the mixture was
irradiated at 160 °C for 40 min. The resulting solution was diluted
with EtOH (8 mL) and KOH (2 pellets) were added and the mixture
was heated to 90 °C for 24 h. The reaction mixture was then concen-
trated under reduced pressure, and the resulting mixture was
suspended in water, pH adjusted to pH 5.3, extracted into EtOAc
(2 × 100 mL), and dried over MgSO4. The mixture was then
concentrated under reduced pressure, triturated with methanol, and
puriﬁed by column chromatography (100% hexane−10% methanol/
ethyl acetate). The resulting solid was recrystallized from dichloro-
methane and diethyl ether and dried to aﬀord the title com-
pound 60 as a bright-yellow solid (3.5 mg, 0.0126 mmol, 3.9%).
1H NMR (400 Hz, DMSO-d6): δ 6.48 (br s, 2H), 7.23 (s, 1H),
7.40−7.42 (m, 1H), 7.51−7.60 (m, 2H), 7.71 (d, 1H, J = 2.2 Hz), 7.73
(br s, 1H), 7.96 (s, 1H), 12.20 (br s, 1H). HRMS (ESI) calculated for
C14H9N6O [M + H]
+ 277.0843, found 277.0851. HPLC: tR = 7.86 min
(method A) (88.64%).
2-Amino-4-(2-(hydroxymethyl)phenyl)-7H-pyrrolo[2,3-d]-
pyrimidine-5-carbonitrile (61). 5 (110 mg, 0.40 mmol), 2-hydroxy-
methylbenzne boronic acid (133 mg, 0.87 mmol), and Pd-118 (31 mg,
0.048 mmol) were suspended in a mixture of IPA/H2O (3:1.5 mL)
and degassed. t-Butylamine (0.21 mL, 2.0 mmol) was added, and the
mixture was irradiated at 160 °C for 40 min. Organics were combined
and concentrated under reduced pressure. The resulting solid was
triturated with diethyl ether, ﬁltered, and dried to aﬀord the title
compound 61 as an oﬀ-white solid (51 mg g, 0.193 mmol, 49%).
1H NMR (400 Hz, DMSO-d6): δ 4.55 (d, 2H, J = 5.6 Hz), 5.09 (t, 1H,
J = 5.8 Hz), 6.64 (br s, 2H), 7.37−7.41 (m, 2H), 7.48 (d of t, 1H,
J = 2.0, 7.2 Hz), 7.61 (d, 1H, J = 7.6 Hz), 8.05 (s, 1H), 12.31 (br s,
1H). HRMS (ESI) calculated for C14H10N5O [M + H]
+ 264.0891,
found 264.0891.
2-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl) -
benzenesulfonamide (62). 5 (130 mg, 0.405 mmol), 2-(sulfamo-
ylphenyl)boronic acid (130 mg, 0.65 mmol), and Pd-118 (28 mg,
0.043 mmol) was suspended in a mixture of IPA/H2O (3 mL:1.5 mL),
and the mixture was degassed under nitrogen. t-Butylamine (0.25 mL,
2.4 mmol) was added, and the reaction mixture was degassed under
nitrogen. The reaction mixture was irradiated with microwaves at
160 °C for 40 min. Once cooled to room temperature, the mixture was
diluted with EtOH (8 mL) and KOH (2 pellets) added. The reaction
mixture was heated to 95 °C for 20 h. The reaction mixture was then
concentrated under reduced pressure. The residue was suspended in
water, and the mixture was pH adjusted to pH 5.5 and extracted with
ethyl acetate and concentrated under reduced pressure. The resulting
solid was triturated with diethyl ether and ﬁltered oﬀ. Further
puriﬁcation was required, and this was carried out using HPLC to
aﬀord the title compound 62 (6.8 mg). 1H NMR (400 MHz, DMSO-
d6): δ 6.82 (br s, 2H), 7.16 (br s, 2H), 7.62 (m, 1H), 7.73 (m, 2H),
8.04 (m, 1H), 8.06 (d, J = 5.0 Hz, 1H), 12.39 (br s, 1H). HRMS (ESI)
calculated for C13H11N6O2S [M + H]
+ 315.0659, found 315.0656.
4-(2-Amino-7H-pyrrol[2,3-d]pyrimidin-4-yl)benzenesulfonamide
(64). 4-Chloro-7H-pyrrolo[2,3-d]pyrimdin-2-amine (70 mg, 0.42 mmol),
4-sulphamoylbenzne boronic acid (133 mg, 0.66 mmol), and Pd-118
(37 mg, 0.057 mmol) were suspended in a mixture of IPA/H2O
(3:1.5 mL) and degassed. t-Butylamine (0.22 mL, 2.09 mmol) was
added, and the mixture was irradiated at 160 °C for 40 min. Once
cooled to room temperature the reaction mixture was diluted with
ethyl acetate and concentrated under reduced pressure. The resulting
solid was puriﬁed by column chromatography (100% hexane−100%
ethyl acetate), triturated with diethyl ether, ﬁltered, and dried to aﬀord
the title compound 64 as a pale-yellow solid (23.7 mg, 0.082 mmol,
20%). 1H NMR (400 Hz, DMSO-d6): δ 6.23 (br s, 2H), 6.61 (d, 1H,
J = 2.0 Hz), 7.17 (d, 1H, J = 2.8 Hz), 7.48 (br s, 2H), 7.98 (d, 2H,
J = 8.4 Hz), 8.2 (d, 2H, J = 8.4 Hz), 11.36 (br s, 1H). HRMS (ESI)
calculated for C12H11N5O2S [M + H]
+ 290.0706, found 290.0703.
HPLC: tR = 8.45 min (method A).
4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)benzenesulfonamide (65).
6-Chloro-7-deazapurine (233 mg, 1.45 mmol), 4-sulfamoylbenzene
boronic acid (408 mg, 2.03 mmol), and 2-amino-2-methylpropane
(0.61 mL, 5.80 mmol) were dissolved in 2-propanol (7.5 mL)
and water (3.75 mL), and the solution degassed with argon.
Dichloro[1,1′ bis(di-tert-butylphosphino)]ferrocene palladium(II)
(94.4 mg, 0.145 mmol) was added, and the mixture was heated at
160 °C for 40 min in a microwave. The reaction mixture was concen-
trated under reduced pressure and puriﬁed by ﬂash column chro-
matography (silica gel with EtOAc (100%)−50% MeOH/EtOAc) to
give the crude product. Trituration of the crude product with DCM/
MeOH (9:1) gave the title compound 65 as a yellow solid (155 mg,
0.57 mmol, 39%). 1H NMR (400 MHz, DMSO-d6): 6.95 (d, 1H, J =
2.0 Hz), 7.52 (s, 2H), 7.27 (dd, 1H, J = 2.8, 2.0 Hz), 8.04 (d, 2H, J =
8.4 Hz), 8.37 (d, 2H, J = 8.4 Hz), 8.89 (s, 1H), 12.41 (br s, 1H).
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HRMS (ESI) calculated for C12H10N4O2S [M + H]
+ 275.0603, found
275.0597.
4-(5-Cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzenesulfonamide
(66). 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile (95 mg,
0.53 mmol), 4-sulfamoylphenylboronic acid (171 mg, 0.85 mmol),
and Pd-118 (35 mg, 0.05) was suspended in a mixture of IPA/H2O
(3 mL:1.5 mL), and the mixture was degassed under nitrogen.
t-Butylamine (0.28 mL, 2.7 mmol) was added, and the reaction mix-
ture was degassed under nitrogen. The reaction mixture was irradiated
with microwaves at 160 °C for 1 h. The reaction mixture was cooled to
room temperature, and the crude material was suspended in methanol,
adsorbed onto silica gel, and concentrated under reduced pressure.
Puriﬁcation was achieved using column chromatography (100%
hexane−50/50 hexane/ethyl acetate−100% ethyl acetate) to aﬀord
the title compound 66 as a beige solid (76 mg, 0.25 mmol, 48%). 1H
NMR (400 MHz, DMSO-d6): δ 7.58 (s, 2H), 8.03 (d, J = 8.0 Hz, 2H),
8.08 (d, J = 8.3 Hz, 2H), 8.73 (s, 1H), 9.06 (s, 1H), 13.52 (s, 1H).
HRMS (ESI) calculated for C13H10O2N5S [M + H]
+ 300.0550, found
300.0546.
4-(Piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (67). 4-Chloro-
7H-pyrrolo[2,3-d]pyrimidin-2-amine (80 mg, 4.76 mmol), NEt3 (0.2 mL,
1.43 mmol), and piperidine (0.15 mL, 1.52 mmol) was suspended in
1,4-dioxane (2.5 mL), which was degassed under nitrogen. The
reaction mixture was irradiated with microwaves at 200 °C for 20 min.
The resulting mixture was diluted with EtOAc (10 mL) and con-
centrated under reduced pressure. Puriﬁcation by column chromatog-
raphy (100% EtOAc−10% MeOH/EtOAc) followed by trituration
with diethyl ether and ﬁltration aﬀorded the title compound 67 as a
white solid (8 mg, 0.04 mmol, 0.8%).1H NMR (400 Hz, DMSO-d6): δ
1.56 (m, 4H), 1.64 (m, 2H), 3.75 (t, J = 5.0 Hz, 4H), 5.49 (br s, 2H),
6.31 (dd, J = 2.0, 3.5 Hz, 1H), 6.72 9dd, J = 2.5, 3.5 Hz, 1H), 10.80
(br s, 2H). HRMS (ESI) calculated for C11H16N5 [M + H]
+ 218.1400,
found 218.1398.
N4-Cyclohexyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine (68). To
2-amino-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (110 mg, 0.73 mmol),
BOP (44 mg, 1.00 mmol), and DBU (0.22 mL, 1.47 mmol) in DMF/
DMSO (1:1, 4 mL) was added cyclohexylamine (0.25 mL, 2.19 mmol)
at room temperature. The reaction mixture was stirred at room tem-
perature for 4 d then heated to 60 °C for 2 h. The reaction mixture
was cooled to room temperature and concentrated under reduced
pressure. The resulting residue was triturated with water and extracted
into EtOAc. The organic layer was concentrated under reduced
pressure to aﬀord the title compound 68 as an yellow solid (50 mg,
0.22 mmol, 30%). 1H NMR (400 Hz, DMSO-d6): δ 1.14 (m, 1H),
1.35 (m, 4H), 1.63 (m, 2H), 1.76 (m, 2H), 1.90 (m, 2H), 6.49 (br s,
2H), 6.63 (s, 1H), 6.85 (s, 1H), 7.36 (br s, 1H), 11.71 (br s, 1H).
LRMS (ESI): calculated for C12H17N5 [M + H]
+ 232.29, found 232.27.
(1R,4R)-4-(2-Amino-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-
cyclohexanol (69). Prepared according to procedure B using 4-chloro-
7H-pyrrolo[2,3-d]pyrimidin-2-amine. Chromatographic puriﬁcation
(Biotage SP4, 10 g cartridge, solvent system: MeOH/DCM; gradient
5% 4CV, 0−20% 10CV, 20% 4CV) yielded 69 (94 mg, 64%) as a ﬂuﬀy
white solid; mp 178−180 °C (d). 1H NMR (400 MHz, DMSO-d6) δ:
1.20−1.36 (m, 4H), 1.84−1.90 (m, 4H), 3.37−3.44 (m, 1H),
3.91−4.01 (m, 1H), 4.54 (d, J = 4.4 Hz, 1H), 5.38 (bs, 2H),
6.31−6.32 (m, 1H), 6.59−6.60 (m, 1H), 6.63 (bs, 1H), 10.57 (bs,
1H). 13C NMR (100 MHz, DMSO-d6) δ: 31.4, 35.0, 48.0, 69.1, 96.5,
99.4, 117.0, 153.2, 156.6, 160.3. HRMS (ESI) calculated for
C12H18ON5 [M + H]
+ 248.1506, found 248.1504. HPLC tR =
7.40 min (method C).
N4-Cyclohexyl-5-(triﬂuoromethyl)-7H-pyrrolo[2,3-d]pyrimidine-
2,4-diamine (70). Prepared according to procedure A using 4-chloro-
5-(triﬂuoromethyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (100 mg,
0.42 mmol). Chromatographic puriﬁcation (Biotage SP4, 10 g cartridge,
solvent system: EtOAc/Hex; gradient 15% 4CV; 15−75% 10CV; 75%
6CV) yielded a brown oil. The oil was dissolved in Et2O (1 mL) and
poured dropwise into Hex (6 mL). The precipitate was ﬁltered oﬀ to
yield 70 (30 mg, 24%) as a light-brown solid; mp 202−204 °C (d). 1H
NMR (400 MHz, DMSO-d6) δ: 1.11−1.20 (m, 3H), 1.25−1.37
(m, 2H), 1.58−1.62 (m, 1H), 1.70−1.74 (m, 2H), 1.88−1.91 (m, 2H),
3.70−3.80 (m, 1H), 6.91 (d, J = 7.3 Hz, 1H), 7.09 (bs, 2H), 7.99
(s, 1H). 13C NMR (100 MHz, DMSO-d6) δ: 25.3, 25.9, 33.1, 49.0,
59.3, 100.0, 105.5, 121.8, 123.9, 147.6, 151.6. HRMS (ESI) calculated
for C13H16N5F3 [M − H]− 298.1285, found 298.1283. HPLC tR =
10.76 min (method A).
2-Amino-4-((1R,4R)-4-hydroxycyclohexylamino)-7H-pyrrolo[2,3-
d]pyrimidine-5-carboxamide (71). 5 (100 mg, 0.56 mmol) and trans-
4-aminocyclohexanol (124 mg, 1.08 mmol) were suspended in
n-BuOH (4 mL) and reﬂuxed for 16 h. After cooling to room
temperature H2O (2 mL) and KOH (2 pellets) were added and the
reaction mixture was heated for 40 min at 150 °C in the microwave
oven. The mixture was neutralized using 6 M HCl and concentrated in
vacuo. The residue was triturated with H2O (4 mL) and dried in
vacuo. The remaining solid was then triturated with Et2O (2 × 10 mL)
and dried in vacuo to aﬀord 71 (91 mg, 87% yield) as a beige solid; mp
>300 °C (d). FTIR (neat): 3441.8, 3352.4, 3130.0, 2938.5, 2854.5,
1628.5, 1593.6, 1507.5, 1451.01, 1417.06 cm−1. 1H NMR (400 MHz,
DMSO-d6) δ: 1.18−1.32 (m, 4H), 1.83−1.85 (m, 2H), 1.95−1.98
(m, 2H), 3.43−3.53 (m, 1H), 3.88−3.96 (m, 1H), 4.54 (d, J = 2.6 Hz,
1H), 5.56 (bs, 2H), 7.00 (bs, 1H), 7.50 (s, 1H), 7.65 (bs, 1H), 9.37
(d, J = 7.7 Hz, 1H), 11.16 (bs, 1H). 13C NMR (100 MHz, DMSO-d6)
δ: 30.7, 33.9, 47.4, 68.4, 95.0, 111.1, 122.1, 154.0, 157.0, 161.1, 168.0.
HRMS (ESI) calculated for C13H19O2N6 [M + H]
+ 291.1564, found
291.1563. HPLC tR = 6.64 min (method C).
IKK Assays. IKKα and IKKβ inhibitory activity was determined
using a dissociation enhanced ligand ﬂuorescent immunoassay
(DELFIA) based on the protocol of HTScan IKKβ kinase assay
(Cell Signaling Technology, USA).
Recombinant IKKα or IKKβ, 37 nM (Millipore, Dundee, UK), was
incubated with IκB-α (Ser32) (New England Biolabs, Hitchin, UK),
biotinylated peptide substrate (0.375 μM), and 40 μM ATP in assay
buﬀer (40 mM Tris-HCl (pH 7.5), 20 mM MgCl2, EDTA 1 mM,
DTT 2 mM, and BSA 0.01 mg/mL) in a V-well 96-well plate in the
presence and absence of test compound. The assay plate was incubated
for 60 min at 30 °C, after which the kinase reaction was quenched by
the addition of 50 mM EDTA, pH 8. The resulting mixture was
transferred to a streptavidin-coated 96-well plate (PerkinElmer,
Beaconsﬁeld, UK) and incubated for 1 h at 30 °C to immobilize the
substrate peptide. After three washes with wash buﬀer (0.01 M
phosphate buﬀered saline (PBS), 0.05% Tween-20, pH 7.4), a primary
antibody against the phosphorylated substrate (phospho-IκB-α)
(Ser32/36) (5A5) mouse mAb (New England Biolabs, Hitchin, UK)
(1:1000 dilution with 1% bovine serum albumin (BSA) in wash buﬀer)
was added and incubated at 37 °C for 2 h.
After a further three washes, a secondary europiated antibody
(Eu−N1 labeled antimouse IgG, (PerkinElmer, Beaconsﬁeld, UK)
diluted 1:500 in 1% BSA/wash buﬀer) was added and incubated at 30 °C
for 30 min. After a further ﬁve washes, DELFIA enhancement solution
(PerkinElmer, Beaconsﬁeld UK) was added and allowed to incubate
for 10 min at room temperature, protected from light, to facilitate the
chemiﬂuorescent detection. The relative ﬂuorescence units (RFU)
signal were measured on a Wallac Victor 1420 multilabel counter
(PerkinElmer, Beaconsﬁeld, UK) in time-resolved ﬂuorescence mode.
The counter was set at an excitation wavelength of 340 nm with a
400 μs delay before detecting emitted light at 615 nm. The apparent Ki
of the phosphorylated substrate was calculated for each compound
using the Cheng−Prusoﬀ equation.
Cell Culture. U2OS cells were cultured with McCoy’s 5A modiﬁed
medium and MEF were cultured with DEME medium containing 10%
(v/v) FCS and medium was changed every 2 d thereafter until cells
became conﬂuent. Cells were incubated at 37 °C in humidiﬁed air with
5% CO2 and rendered quiescent by serum deprivation for 24 h prior to
stimulation in serum-free medium.
Western Blot Analysis. Whole cell lysates were prepared from
U2OS and status of IκBα, p65, p-p65 (Ser536), and p-p100 (Ser 866/
870) assessed by Western blotting as described in Mackenzie et al.
(2007).46
NFκB Transcriptional Activity Assays. An adenoviral vector
encoding NFκB-luciferase (Adv.NFκB-Luc) was purchased from Vector
Biolabs (University of Pennsylvania, Philadelphia, US). Large-scale
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production of high titer recombinant adenovirus was performed by
routine methods.47 IKKβ knockout mouse embryonic ﬁbroblasts
(MEFs; kindly provided by Prof. I. Verma, UCSD, USA) were counted
when approximately 60−70% conﬂuent in T75 cm2 ﬂasks and infected
with adenovirus up to 300 pfu/cell−1 for 24 h in 10% DMEM. Cells
were then lifted from the ﬂasks and plated into 96-well clear bottom,
black luciferase plates and allowed to settle for 24 h before serum
starved overnight. Cells were then stimulated with the appropriate
agonists for the indicated times and reactions terminated by addition
of lysis buﬀer containing 0.2 mM luciferin substrate. Relative light
units (RLU) were measured using a Trilux microbeta counter
(luminometer).
Kinase Proﬁling. Kinase proﬁling of compound 48 was outsourced
to Millipore, speciﬁcally the Kinase Proﬁler Customer Service for
single concentration studies using duplicate assay points.
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